<rss version="2.0"><channel><title>经济学家</title><description>经济学人全文RSS。获取更多全文RSS：https://feedx.net</description><link/> https://www.economist.com <item><title><![CDATA[A spy for China in Britain’s Parliament? | Britain]]></title><link/><![CDATA[https://www.economist.com/britain/2023/09/12/a-spy-for-china-in-britains-parliament]]><description> &lt;img src=&quot;https://images.weserv.nl/?url=www.economist.com/img/b/1280/720/90/media-assets/image/20230916_BRP502.jpg&quot;/>;&lt;div>;&lt; /div>;&lt;p data-caps=&quot;initial&quot;>;&lt;span data-caps=&quot;initial&quot;>;T&lt;/span>;&lt;small>;HE NEWS&lt;/small>; 一名英国议会研究员因涉嫌从事间谍活动而被捕中国似乎倒退到了冷战时期，当时苏联曾招募年轻男女作为特工。报道此事的《星期日泰晤士报》称，这名助手此前曾接触过英国安全大臣汤姆·图根哈特和外交事务负责人艾丽西亚·卡恩斯等议员。议会特别委员会。两人都以对中国的强硬立场而闻名。尽管嫌疑人否认了这些指控，但这起案件却让人们关注英国应如何与中国共产党打交道。 &lt;/p>;&lt;p>;这并不是第一次对中国试图影响决策者的邪恶行为的指控。 2022 年，有消息称，一名工党议员接受了律师克里斯汀·李 (Christine Lee) 的捐款，英国安全机构称，李多年来一直代表 &lt;small>;CCP&lt;/small>; 与政界人士建立联系。本案有所不同：涉及一名英国公民，可能是在中国工作时被招募的；与公开支持&lt;小>;中共&lt;/小>;的李女士不同，嫌疑人似乎并没有公开表达过这样的观点。&lt;/p>;&lt;div>;&lt;div>;&lt;div id=&quot;econ-1&quot;>; &lt;/div>;&lt;/div>;&lt;/div>;&lt;p>;下议院情报与安全委员会 (&lt;small>;ISC&lt;/small>;) 7 月份的一份报告猛烈抨击了政府对已经瞄准的中国情报部门的反应该国“多产且积极”。在其他国家，正是发生了像困扰威斯敏斯特的丑闻一样，才改变了政策。在中国政府干预行动被曝光后，澳大利亚和新西兰加强了法律并改变了政治优先事项。&lt;/p>;&lt;p>;英国助手和另一名男子于 3 月被捕，但直到 9 月 10 日才公布了很少的细节。一些保守党议员呼吁总理苏纳克将中国指定为正式的“威胁”，而不是目前的“系统性竞争对手”。自戴维·卡梅伦 (David Cameron) 统治时期商业利益占主导地位以来，政府对中国的立场变得更强硬。&lt;/p>;&lt;p>;7 月，新的《国家安全法》更新了《官方机密法》，纳入了更广泛的间谍活动，特别是“政治间谍活动”。影响活动”——指的是改变人们行为方式的未公开的尝试。将中国列为威胁意味着任何在英国为北京政府或与其有联系的公司或机构工作的人将来都必须根据计划中的外国影响力登记计划进行登记。该规定将于明年生效。 &lt;/p>;&lt;p>;然而，关于塑造中国品牌的大部分争论只是心怀不满的保守党的作秀而已。英国对于如何与中国接触没有明确的政策，尽管外交大臣詹姆斯·克莱弗利(James Cleverly)刚刚访问了北京，这是自 2018 年以来高级官员的首次访问。在涉嫌间谍事件曝光后，苏纳克告诉中国总理李强表示，任何破坏英国民主的行为都是“完全不可接受的”。&lt;/p>;&lt;div>;&lt;div>;&lt;div id=&quot;econ-2&quot;>;&lt;/div>;&lt;/div>;&lt;/div>;&lt;政府也没有办法更广泛地防止中国潜在的恶意影响。例如，伦敦国王学院的研究人员将于 9 月 13 日发布的一份报告指出，大学在研究方面依赖于与中国大学的合作。然而，&lt;small>;ISC&lt;/small>;在 7 月份指出，这些机构没有能力评估此类合作带来的任何潜在风险。保护关键基础设施免受中国干预的官方努力确实存在。阻止中国公司购买拥有可用于军事用途的专业知识的英国公司的努力也是如此。但政府在协调这些努力方面做得很差。&lt;/p>;&lt;p>;全球打击跨国有组织犯罪倡议组织的马丁·索利 (Martin Thorley) 表示，逮捕政府核心的可疑间谍的影响尚不清楚。小>;非政府组织&lt;/小>;。如果属实，那么这位研究人员为中国所做的工作会让政府感到尴尬。索利先生表示，这次逮捕还可能表明，随着英国在 2022 年对李女士采取行动，当局最终将更加强有力地对抗中国的努力。&lt;/p>;&lt;p>;不过，议会可能仍然很脆弱。 &lt;small>;国会议员&lt;/small>;应该审查和影响外交政策，但他们缺乏资源，而且人员预算也很少。因此，他们通常依靠收入微薄的年轻毕业生来撰写演讲和开展研究。鉴于此类助手的招募和审查制度不够专业，议会制度仍然容易受到外国进一步干涉。那些被民主宝座上的可疑间谍戏剧所吸引的人可以期待续集。&lt;span data-ornament=&quot;ufinish&quot;>;■&lt;/span>;&lt;/p>;</description><pubDate> Thu, 14 Sep 2023 10:57:02 +0800</pubDate> </item><item><title><![CDATA[Join The Economist’s team of journalists in London | News]]></title><link/><![CDATA[https://www.economist.com/news/2023/09/11/join-the-economists-team-of-journalists-in-london]]><description> &lt;img src=&quot;https://images.weserv.nl/?url=www.economist.com/img/b/1280/720/90/media-assets/image/20230107_BLP506.jpg&quot;/>;&lt;div>;&lt; /div>;&lt;p>;我们正在寻找一位有才华、有进取心、适应性强的人才加入《经济学人》数字部门，进行为期一年的带薪实习。 &lt;/p>;&lt;p>;实习将涉及：&lt;/p>;&lt;ul>;&lt;li>;数字出版：作为全球团队的一部分，开发 Espresso 新闻应用程序和 Newsdesk&lt;/li>;&lt;li>;故事的工作流程，与不同部门联络并发布文章&lt;/li>;&lt;li>;策划主页和应用程序&lt;/li>;&lt;li>;推销和撰写文章，包括解释和每日图表&lt;/li>;&lt;/ul>;&lt;p >;实习生将在数字团队工作，但也能为其他部门做出贡献，从周刊到播客再到电影。偶尔需要周末轮班。&lt;/p>;&lt;div>;&lt;div>;&lt;div id=&quot;econ-1&quot;>;&lt;/div>;&lt;/div>;&lt;/div>;&lt;p>;实习计划的目的是寻找并培训未来的&lt;i>;经济学家&lt;/i>;记者。以前的新闻经验不是必需的，但候选人应该具有出色的写作和分析能力。他们应该对世界充满好奇，并且能够简洁、诙谐、严谨地书写它。实习生应该很快熟悉《经济学人》的风格指南。&lt;/p>;&lt;p>;理想情况下，候选人应该对我们的“后半部分”主题表现出兴趣：商业、金融、经济、技术或科学。&lt;/p>;&lt;p>;他们还需要精心组织，对细节有敏锐的洞察力，并能够轻松地学习与不同的出版系统合作。您将成为由其他数字记者组成的全球但紧密的团队的一员；团队合作技能至关重要。&lt;/p>;&lt;p>;要申请，请发送一封简短的求职信、&lt;small>;简历&lt;/small>;和三个原创“块”，每块约 150 字，适合在 World in Brief 上发表，到 &lt;a href=&quot;https://www.economist.com/cdn-cgi/l/email-protection#e3878a848a97828f8a8d9786918da386808c8d8c8e8a9097cd808c8e&quot;>;&lt;span data-cfemail=&quot;6d09040a04190c01040319081f 032d080e02030200041e19430e0200&quot;>;[电子邮件受保护]&lt;/span >;&lt;/a>;。前瞻性的迷你文章，大块地解释了某一天将要发生的事情以及为什么它很重要——或者就议程设置项目而言，解释了未来几周和几个月内将发生的事情。您可以在我们的&lt;a href=&quot;https://www.economist.com/the-world-in-brief&quot;>;网站&lt;/a>;和应用程序的“世界简介”部分查看示例。您提交的至少两个部分应与商业、金融、经济、技术或科学相关。截止日期是10月7日。&lt;/p>;&lt;p>;书面作业是申请中最重要的部分。我们将盲读这些内容（即不查看您的姓名或背景）。&lt;/p>;&lt;p>;这份工作位于伦敦。所有申请人必须拥有在英国工作的合法权利。&lt;/p>;&lt;p>;&lt;i>;经济学人集团是国际商业和世界事务分析的主要来源。我们通过各种形式提供信息，从报纸和杂志到会议和电子服务。将我们联系在一起的是我们观点的客观性、我们见解的原创性以及我们对世界各地经济和政治自由的倡导。&lt;/i>;&lt;/p>;&lt;p>;&lt;i>;经济学人集团重视多样性。我们致力于为所有员工提供平等机会并创造一个包容的环境。我们欢迎申请人，无论民族、国籍、性别、种族、肤色、宗教信仰、残疾、性取向或年龄。&lt;/i>;&lt;/p>;</description><pubDate> Thu, 14 Sep 2023 08:27:09 +0800</pubDate> </item><item><title><![CDATA[Martin Indyk reflects on the Oslo accords, 30 years on | By Invitation]]></title><link/><![CDATA[https://www.economist.com/by-invitation/2023/09/12/martin-indyk-reflects-on-the-oslo-accords-30-years-on]]><description> &lt;img src=&quot;https://images.weserv.nl/?url=www.economist.com/img/b/1280/720/90/media-assets/image/20230916_BID001.jpg&quot;/>;&lt;div>;&lt; /div>;&lt;p>;&lt;small>;30 年前的这一周，华盛顿一个万里无云的早晨，以色列总理伊扎克·拉宾 (Yitzhak Rabin) 和巴勒斯坦解放组织 (PLO) 主席亚西尔·阿拉法特 (Yasser Arafat)在白宫草坪上握手并承诺结束以巴冲突。尽管美国没有参与谈判，但比尔·克林顿总统站在两人身后，他伸出双手象征着美国将为和平缔造者提供的支持。克林顿先生在演讲中向以色列人和巴勒斯坦人承诺“正常生活的安静奇迹”。&lt;/p>;&lt;p>;可悲的是，从那时起，他们的生活就不再平静或正常了。和平的希望被猛烈的暴力之火吞噬，现在已经演变成巴勒斯坦恐怖袭击和以色列报复的长期针锋相对。&lt;/p>;&lt;div>;&lt;div>;&lt;div id=&quot;econ-1 &quot;>;&lt;/div>;&lt;/div>;&lt;/div>;&lt;p>;1993 年签署的框架协议是奥斯陆协议中的第一个，很容易被视为失败的和平倡议而被驳回。但到底是协议失败了，还是政治家和政界人士未能抓住外交提供的机会？答案很重要。当以色列和巴勒斯坦权力机构现任领导人本雅明·内塔尼亚胡和马哈茂德·阿巴斯分别离开现场时，他们留下的奥斯陆外交废墟可能会被重新塑造为一次有意义的努力，为和平提供另一次机会。&lt;/p>;&lt;人们普遍认为奥斯陆协议是理想主义的，甚至是幻想的。事实上，它基于一个现实的假设，即双方都没有准备好实现持久和平。因此，奥斯陆会议的目的是缓和冲突，而不是结束冲突。没有建立巴勒斯坦国的规定或必要的安全安排，没有提到耶路撒冷，也没有提到巴勒斯坦难民。这些都是以后要处理的“最终地位问题”；经过数十年的血腥冲突，他们被认为过于复杂、过于虔诚和充满情感。 &lt;/p>;&lt;p>;相反，奥斯陆提供了渐进的和解过程。根据该协议组建的巴勒斯坦权力机构将在以色列军队分阶段撤军的同时，逐步承担起对约旦河西岸和加沙地带的领土和巴勒斯坦居民的责任。&lt;/p>;&lt;p>;两年后，感觉就像是奥斯陆进程正在发挥作用。阿拉法特不是一个容易接受的顾客。对于一个走在改革之路上的头号恐怖分子来说，治理、透明度和法治并不是自然而然的。但拉宾和他的缔造和平伙伴西蒙·佩雷斯对于自己面对的是谁并不抱有任何幻想。他们找到了鼓励阿拉法特承担更大责任，维护目前在他控制下的巴勒斯坦人的秩序的方法。正如奥斯陆进程所设想的那样，领导人之间（如果还没有在人民之间）建立信任。&lt;/p>;&lt;div>;&lt;div>;&lt;div id=&quot;econ-2&quot;>;&lt;/div>;&lt;/ div>;&lt;/div>;&lt;p>;1995年9月的奥斯陆第二次协议达到了高潮。在签署仪式结束时，拉宾在白宫草坪上不情愿的握手被阿拉法特兄弟般的手臂搭在了拉宾的肩上。当天晚上，阿拉法特就与以色列实现和平发表了热情洋溢的讲话。拉宾指出，他的演讲能力似乎“有点犹太人”。&lt;/p>;&lt;p>;六周后，拉宾被一名认同定居者运动的犹太极端分子暗杀。佩雷斯挺身而出，但被哈马斯、伊朗支持的真主党和伊斯兰圣战组织共同推翻奥斯陆协议的努力所压倒。在随后的选举中，内塔尼亚胡与奥斯陆展开较量，并以微弱优势击败佩雷斯。 &lt;/p>;&lt;p>;尽管内塔尼亚胡先生无法废除奥斯陆进程，但鉴于该进程享有广泛的国际支持，他仍然希望阻止该进程。克林顿花了两年时间才说服他完成奥斯陆临时进程的第二阶段，导致以色列从约旦河西岸区区 13% 的领土撤出。与此同时，内塔尼亚胡先生让定居者运动扩大在西岸和加沙的建设，这与奥斯陆的精神背道而驰。然而，这并没有安抚内塔尼亚胡先生的右翼选民，当他敢于同意撤回领土时，他们推翻了他的政府。&lt;/p>;&lt;p>;奥斯陆在以色列仍然为工党的继任者埃胡德·巴拉克（Ehud Barak）提供了足够的支持。拉宾赢得随后的选举。但他的联合政府摇摇欲坠，他怀疑自己能否继续迈出另一步。相反，他说服克林顿放弃奥斯陆再次临时撤军的要求，转而尝试于 2000 年 7 月在戴维营一举解决所有最终地位问题。巴拉克先生寻求结束冲突、结束索赔的和平协议，这与奥斯陆的渐进主义相反。&lt;/p>;&lt;p>;阿拉法特很诚实地告诉克林顿先生，他还没有准备好结束冲突，并坚持认为而是临时撤回。但克林顿的任期已经过去了，全面和平的诱惑比另一次看似无休止的争取较小协议的努力更具吸引力。于是，克林顿和巴拉克把阿拉法特拖到了戴维营，并向他提出了一份慷慨的提议。当阿拉法特犹豫不决时，克林顿先生将崩溃归咎于他，巴拉克先生则宣称以色列没有巴勒斯坦和平伙伴。&lt;/p>;&lt;p>;巴勒斯坦街头爆发了愤怒，将以色列提供的一些枪支转给了巴勒斯坦人。警察反而针对以色列士兵。以色列也做出了愤怒的回应。阿拉法特不愿与人民对抗，试图骑虎难下。随后的&lt;i>;起义&lt;/i>;持续了五年，导致双方数千人死亡。从克林顿到唐纳德·特朗普，美国历届总统都无法重启和平进程。&lt;/p>;&lt;p>;奥斯陆会议一开始就失败了，因为双方都违反了各自的承诺。巴勒斯坦人并没有放弃恐怖；以色列人在表面上为巴勒斯坦人保留的土地上寻求定居点，而美国无法让他们信守诺言。但奥斯陆会议也失败了，因为美国和以色列放弃了渐进进程，转而达成最终协议，而这一协议至今仍无法实现。&lt;/p>;&lt;div>;&lt;div>;&lt;div id=&quot;econ-3&quot;>;&lt;/div>;&lt; /div>;&lt;/div>;&lt;p>;具有讽刺意味的是，奥斯陆协议仍然是以色列与巴解组织之间达成的唯一具有约束力的协议。它们是巴勒斯坦权力机构合法性的源泉，尽管巴勒斯坦权力机构实力薄弱，但仍然负责管理西岸的巴勒斯坦人，并控制名义上至少 40% 的领土。这些协议还管理以色列和巴勒斯坦权力机构之间的经济关系。今年二月，内塔尼亚胡领导的以色列政府（其中包含决心摧毁巴勒斯坦权力机构的极右翼政党）重申了奥斯陆协议。&lt;/p>;&lt;p>;当双方最终都有愿意做出真正努力的领导人时奥斯陆关于进一步移交西岸领土的难以捉摸的条款仍然记录在案，并有能力动员公众支持，这可能是重启逐步重建信任进程的第一步。牵强吗？这正是美国、沙特阿拉伯和巴勒斯坦权力机构正在讨论的问题，作为美国与以色列和沙特阿拉伯之间谈判达成的和平协议的巴勒斯坦部分。&lt;/p>;&lt;p>;奥斯陆进程已死；奥斯陆进程万岁。 &lt;/p>;&lt;p>;&lt;i>;马丁·因迪克 (Martin Indyk) 是纽约外交关系委员会的洛伊杰出研究员。在签署奥斯陆协议时，他是比尔·克林顿总统的中东特别助理。他曾两度担任美国驻以色列大使和巴拉克·奥巴马总统的以色列-巴勒斯坦谈判特使。 &lt;/i>;&lt;/p>;&lt;br>;&lt;hr>;&lt;div>;获取更多RSS：&lt;br>;&lt;a href=&quot;https://feedx.net&quot; style=&quot;color:orange&quot; target=&quot;_blank&quot; >;https://feedx.net&lt;/a>; &lt;br>;&lt;a href=&quot;https://feedx.best&quot; style=&quot;color:orange&quot; target=&quot;_blank&quot;>;https://feedx.best&lt;/一个>;&lt;br>;&lt;/div>;</description><pubDate> Thu, 14 Sep 2023 08:27:09 +0800</pubDate> </item><item><title><![CDATA[The plucky firms that are beating big tech | Business]]></title><link/><![CDATA[https://www.economist.com/business/2023/09/12/meet-the-plucky-firms-that-are-beating-big-tech]]><description> &lt;img src=&quot;https://images.weserv.nl/?url=www.economist.com/img/b/1280/720/90/media-assets/image/20230916_WBD001.jpg&quot;/>;&lt;div>;&lt; /div>;&lt;p data-caps=&quot;initial&quot;>;&lt;span data-caps=&quot;initial&quot;>;B&lt;/span>;&lt;small>;IG TECH&lt;/small>; 不断壮大。今年到目前为止，美国五家数字巨头——Alphabet、亚马逊、苹果、Meta 和微软——的总市值已飙升一半，达到 9 万亿美元左右。这几乎是美国最大公司指数&lt;small>;S&lt;/small>;&amp;&lt;small>;P&lt;/small>; 500 指数总数的四分之一（该指数在此期间仅上涨了 17%）。这五家公司的销售额、利润和研发支出几乎占该指数中所有科技公司的 60%。人们普遍认为他们将成为人工智能（&lt;small>;AI&lt;/small>;）革命的主要赢家。 &lt;/p>;&lt;p>;各国政府对这种主导地位越来越感到恐惧。 9 月 12 日，美国司法部开始在法庭上与谷歌及其母公司 Alphabet 展开对峙，这是二十年来最大的反垄断案件，指控谷歌滥用其互联网搜索垄断地位。本月，欧盟的一项法律将五巨头标记为数字“看门人”，禁止他们捆绑某些服务并在其平台上歧视第三方等。世界反垄断人士认为，科技巨头已经发展得如此庞大，以至于它们吸走了科技生态系统中的所有氧气，导致挑战者走向灭亡，或者充其量也让其他任何人都难以繁荣。问问 Snap、Spotify 或 Zoom 就知道了。 &lt;/p>;&lt;div>;&lt;div>;&lt;div id=&quot;econ-1&quot;>;&lt;/div>;&lt;/div>;&lt;/div>;&lt;p>;与自然生态系统一样，商业生态系统也为新来者提供了机会。为了继续以投资者预期的惊人速度增长，五巨头最关注足以对其收入产生有意义影响的广阔市场，去年的收入总计达到 1.5 万亿美元。这意味着他们忽略了某些规模较小但仍可能有利可图的领域。那些聪明的公司发现了这些利基市场并能够利用它们，不仅能生存下去，而且还能在巨头的阴影下蓬勃发展。 &lt;/p>;&lt;p>;以 Garmin 为例。该公司成立于 1989 年，率先将 &lt;small>;GPS&lt;/small>; 导航系统商业化。到 2008 年，它已经占领了便携式导航设备近三分之一的市场，主要是安装在汽车仪表板上的设备，约占该公司销售额的 72%。随后，谷歌发布了谷歌地图应用程序，首先是在 2008 年，针对 Android 智能手机，然后是四年后，针对 iPhone。此时，驾车者可以简单地使用手机来找到路，而不必花钱购买专用设备。到 2014 年，Garmin 汽车部门的收入与六年前相比下降了一半，至 12 亿美元。 &lt;/p>;&lt;div>;&lt;figure>;&lt;span itemscope=&quot;&quot; itemProp=&quot;image&quot; itemType=&quot;https://schema.org/ImageObject&quot; data-slim=&quot;1&quot;>;&lt;meta itemProp=&quot;url&quot; 内容=&quot;https://www.economist.com/img/b/608/890/90/media-assets/image/20230916_EPC554.png&quot;/>;&lt;img loading=&quot;lazy&quot; src=&quot;https://www.economist.com/img/b/608/890/90/media-assets/image/20230916_EPC554.png&quot;/>; economics.com/img/b/608/890/90/media-assets/image/20230916_EPC554.png&quot; srcSet=&quot;https://www.economist.com/img/b/200/293/90/media-assets /image/20230916_EPC554.png 200w，https://www.economist.com/img/b/300/439/90/media-assets/image/20230916_EPC554.png 300w，https://www.economist.com/img /b/400/586/90/media-assets/image/20230916_EPC554.png 400w，https://www.economist.com/img/b/600/878/90/media-assets/image/20230916_EPC554.png 600w ，https://www.economist.com/img/b/640/937/90/media-assets/image/20230916_EPC554.png 640w，https://www.economist.com/img/b/800/1171/ 90/media-assets/image/20230916_EPC554.png 800w，https://www.economist.com/img/b/1000/1464/90/media-assets/image/20230916_EPC554.png 1000w，https://www. economics.com/img/b/1280/1874/90/media-assets/image/20230916_EPC554.png 1280w&quot;sizes=&quot;336px&quot; alt=&quot;&quot;/>;&lt;/span>;&lt;/figure>;&lt;p>;一年后大型科技公司再次遭受打击。苹果推出了首款智能手表，这可能会损害 Garmin 不断增长的健身和户外运动设备销售业务。不过，这一次，规模较小的公司经受住了攻击（见图 1）。它专注于高端手表和健身追踪器，其中一些产品的售价是高端 Apple Watch 的数倍。通过这样做，它建立了一个由登山者、跑步者和其他各类健身狂热者组成的忠实用户群；四月，Meta 狂热运动老板马克·扎克伯格 (Mark Zuckerberg) 在及时完成 5 公里跑步后发布了一张他的 Garmin 手表的照片。 &lt;/p>;&lt;/div>;&lt;div>;&lt;div>;&lt;div id=&quot;econ-2&quot;>;&lt;/div>;&lt;/div>;&lt;/div>;&lt;div>;&lt;figure>;&lt;span itemscope=&quot;&quot; itemProp= “图像”itemType =“https://schema.org/ImageObject”data-slim =“1”>; &lt;meta itemProp =“url”content =“https://www.economist.com/img/b/608/ 662/90/media-assets/image/20230916_EPC541.png&quot;/>;&lt;img loading=&quot;lazy&quot; src=&quot;https://www.economist.com/img/b/608/662/90/media-assets/图片/20230916_EPC541.png&quot; srcSet=&quot;https://www.economist.com/img/b/200/218/90/media-assets/image/20230916_EPC541.png 200w,https://www.economist.com/ img/b/300/327/90/media-assets/image/20230916_EPC541.png 300w，https://www.economist.com/img/b/400/436/90/media-assets/image/20230916_EPC541.png 400w，https://www.economist.com/img/b/600/653/90/media-assets/image/20230916_EPC541.png 600w，https://www.economist.com/img/b/640/697 /90/media-assets/image/20230916_EPC541.png 640w，https://www.economist.com/img/b/800/871/90/media-assets/image/20230916_EPC541.png 800w，https://www .economist.com/img/b/1000/1089/90/media-assets/image/20230916_EPC541.png 1000w，https://www.economist.com/img/b/1280/1394/90/media-assets/ image/20230916_EPC541.png 1280w&quot; Sizes=&quot;336px&quot; alt=&quot;&quot;/>;&lt;/span>;&lt;/figure>;&lt;p>;投资公司 Upslope Capital 的乔治·利瓦达斯 (George Livadas) 认为，Garmin 是少数几家拥有在市场上创建了一个优质品牌，并提供了苹果的替代品。如今，其年总收入接近 50 亿美元，大约是第一款 Apple Watch 上架时的两倍。智能手表和健身追踪器贡献了该公司近 60% 的销售额（其余大部分来自船舶和飞机的专业导航系统，见图 2）。 &lt;/p>;&lt;p>;另一家成功利用服务不足的技术利基市场的公司是 Dropbox。苹果联合创始人史蒂夫·乔布斯(Steve Jobs)曾将这家位于旧金山的云存储公司斥为“功能，而不是产品”。该公司成立于 2008 年，一生都在与苹果、谷歌和微软（有一段时间是亚马逊）竞争。它的较大竞争对手都将云存储与其他服务捆绑在一起。例如，注册谷歌 Gmail 的客户可以获得一些免费的在线存储空间。但这些产品虽然通常是免费的，但缺乏 Dropbox 的功能。&lt;/p>;&lt;p>;根据加拿大皇家银行的 Rishi Jaluria 的说法，Dropbox 很早就认识到许多用户需要的不仅仅是一个存储文件的地方。举一个例子，摄影师和其他创意人士希望存储高分辨率文件，而不必担心文件大小。这些要求较高的用户通常愿意为便利而付费。通过开发吸引他们的功能（最近推出了一个由&lt;small>;AI&lt;/small>;驱动的搜索工具来查找和汇总文档），Dropbox 不断吸引新订阅者。 &lt;/p>;&lt;p>;可利用的利基市场也可以是地理上的。阿根廷电子商务公司 MercadoLibre 就是一个很好的例子。当亚马逊分别于 2012 年和 2013 年进入其最大的市场巴西和墨西哥时，它的日子似乎已经屈指可数了。并非如此。十年后，MercadoLibre 占拉丁美洲所有电子商务贸易的四分之一。亚马逊最接近挑战这家地区性购物巨头的地方是墨西哥，但即使在那里，其市场份额也只有竞争对手的一半。 &lt;/p>;&lt;/div>;&lt;p>;MercadoLibre 的成功在于根据当地情况调整其商业模式。它很快发现基础设施薄弱是增长的障碍，这增加了卖家的成本并降低了购物者的购买体验。在过去十年中，该公司投资建设了自己的物流网络，该网络负责运输其 90% 的包裹。其支付服务 MercadoPago 在欺诈猖獗的地区是一种受欢迎的选择。像提供免费送货积分这样的小创新帮助它赢得了对价格敏感的拉丁美洲人的青睐。该公司还发挥其本土根源来赢得客户。其商务主管 Ariel Szarfsztejn 将其描述为“由拉丁美洲人建造”。 4 月份，随着亚马逊在全球范围内裁员，MercadoLibre 宣布计划雇用 13,000 名员工。&lt;/p>;&lt;h2>;见证适应性&lt;/h2>;&lt;p>;找到自己的利基市场并不足以保证大型科技挑战者的成功。 Garmin、Dropbox 和 MercadoLibre 还有其他优势。这三者中至少仍有一位创始人担任高管职务。要想战胜大型科技公司，需要全神贯注于产品开发和长期投资的胃口。让经验丰富的运营商掌舵是有帮助的，他们不会仅仅受到季度目标的影响。 &lt;/p>;&lt;p>;至关重要的是，这三家公司还能赚钱——在利率上升之际，这对投资者来说是一个很大的卖点，这使得科技公司未来利润的承诺不如此时此刻的收益有吸引力。 2022 年，Garmin、Dropbox 和 MercadoLibre 的净利润分别为 9.74 亿美元、5.53 亿美元和 4.8 亿美元。这只是 Alphabet 600 亿美元或苹果 1000 亿美元的一小部分。但对于智能手表、云和电子商务业务来说，这三家公司的营业利润率看起来都很健康。自 2015 年以来，Garmin 的市值增长了两倍，达到超过 200 亿美元。 MercadoLibre 的销售额增长了五倍，达到 700 亿美元。 Dropbox 的估值为 100 亿美元，与疫情期间数字化狂热时期的峰值相差不远。谁说过关于灭绝的事？ &lt;span data-ornament=&quot;ufinish&quot;>;■&lt;/span>;&lt;/p>;</description><pubDate> Thu, 14 Sep 2023 08:27:09 +0800</pubDate> </item><item><title><![CDATA[Ukraine’s small Jewish community is thriving | Europe]]></title><link/><![CDATA[https://www.economist.com/europe/2023/09/11/ukraines-small-jewish-community-is-thriving]]><description> &lt;img src=&quot;https://images.weserv.nl/?url=www.economist.com/img/b/1280/720/90/media-assets/image/20230916_EUP501.jpg&quot;/>;&lt;div>;&lt; /div>;&lt;p>;&lt;i>;阅读我们最近对&lt;a href=&quot;https://www.economist.com/ukraine-crisis&quot;>;乌克兰战争&lt;/a>;&lt;/i>;的更多报道&lt;/p >;&lt;/aside>;&lt;p data-caps=&quot;initial&quot;>;&lt;span data-caps=&quot;initial&quot;>;N&lt;/span>;&lt;small>;俄罗斯可以向他们扔的东西&lt;/small>;将阻止多达 30,000 人，其中大部分是外国人本周，犹太人开始前往基辅以南 200 公里处的乌克兰小镇乌曼进行一年一度的朝圣活动。犹太新年是 9 月 15 日至 17 日，游客将在布雷斯洛夫纳赫曼 (Nachman of Breslov) 的坟墓前祈祷来纪念这一节日。纳赫曼是一位拉比，200 多年前创立了哈西德派的一个重要分支。&lt;/p>;&lt;朝圣是最近乌克兰和以色列政府之间的争吵的焦点。乌克兰威胁要禁止以色列朝圣者进入该国，因为以色列一直在驱逐涉嫌违反签证规定的乌克兰人。但这些争论主要源于以色列是否愿意向乌克兰提供军事帮助的分歧，目前已基本得到解决。事实上，犹太-乌克兰关系现在正处于黄金时代。&lt;/p>;&lt;div>;&lt;div>;&lt;div id=&quot;econ-1&quot;>;&lt;/div>;&lt;/div>;&lt;/div>;&lt;p>;首先，乌克兰总统弗拉基米尔·泽伦斯基是犹太人。基辅的拉比摩西·阿兹曼表示，这一事实对克里姆林宫来说“非常令人不安”。它揭露其“去纳粹化”乌克兰的战争目标是无稽之谈。尽管如此，弗拉基米尔·普京仍然坚持重复这一点。 9 月 5 日&lt;!--->; 俄罗斯总统进入了完全阴谋模式，称泽伦斯基先生是被他的“西方策展人”置于他的位置，这使得“整个情况极其令人厌恶，因为一个犹太人正在掩盖对纳粹主义的美化。”&lt;/p>;&lt;p>;去年，入侵前一天，哈尔科夫的犹太学校庆祝了建校 30 周年。几天后，它在俄罗斯的袭击中受损；该社区附近的宗教学院受到直接打击。 “我们的学校无法正常运转，因为火箭袭击了它们，”学校校长米里亚姆·莫斯科维茨（Miriam Moskovitz）说。 “这与纳粹无关”。&lt;/p>;&lt;p>;第二次世界大战之前，犹太人在现在的乌克兰境内占了很大一部分；其中 1.5 万人在大屠杀中丧生。数万名乌克兰辅助人员帮助德国人犯下了这一罪行，尽管有超过 700 万人作为红军部队与纳粹作战。&lt;/p>;&lt;p>;对于年长的犹太人来说，乌克兰这个名字几乎是“大屠杀”一词的代名词。乌克兰的民族英雄，如 17 世纪的哥萨克指挥官博赫丹·赫梅利尼茨基 (Bohdan Khmelnytsky)，被犹太人铭记为造成数千人死亡的罪魁祸首。如今，许多乌克兰人崇敬斯捷潘·班德拉 (Stepan Bandera)，他的追随者在 1944 年之后与红军作战。他们对班德拉追随者杀害波兰人和犹太人的行为知之甚少，或者选择不知道。&lt;/p>;&lt;p>;过去的乌克兰人经常将一切事情归咎于犹太人，包括共产主义的艰辛。分析人士叶夫亨·赫利博维茨基 (Yevhen Hlibovytsky) 表示，现在，反犹太主义正在消退，就像犹太人对乌克兰人的恐惧一样。 “在苏联长大的一代人反映了苏联实行的很多反犹太主义。我这一代人对此更加自由，我的孩子们也将种族和宗教多样性视为正常。”&lt;/p>;&lt;div>;&lt;div>;&lt;div id=&quot;econ-2&quot;>;&lt;/div>;&lt;/div>; &lt;/div>;&lt;p>;美国皮尤研究中心发现，乌克兰人是欧洲反犹太主义最少的人之一。其中一项民意调查发现，只有 5% 的乌克兰人表示他们不准备接受犹太人作为同胞。相比之下，俄罗斯为 14%，波兰为 18%，希腊为 16%。&lt;/p>;&lt;p>;总部位于维也纳的 Centropa 组织的主管爱德华·塞罗塔 (Edward Serotta) 表示，对许多人来说，“这可能会有些意外”致力于保存中欧和东欧犹太人的记忆。不是对他。乌克兰人正在热情地了解他们国家的犹太历史。今年 3 月 210 年，乌克兰教师申请了 60 个关于如何使用 Centropa 资源的研讨会的名额，然后长途跋涉数小时才到达这些地点。&lt;/p>;&lt;p>;没有人确切知道乌克兰还剩下多少犹太人，而且无论如何数字取决于谁算为一。根据伦敦犹太政策研究所的数据，1989 年，“核心”犹太人口（那些被认为是完全犹太人的人）为 487,000 人。大多数人在苏联解体后移居国外，到 2021 年估计将有 43,000 人。（使用更广泛定义的数字超过 200,000 人。）&lt;/p>;&lt;p>;犹太人对乌克兰的怀疑态度逐渐消退，这在援助规模上得到了证实。自战争开始以来，犹太组织就已将其带入该国。总部位于英国的世界犹太人救济组织已通过各种方式帮助了 236,206 人。犹太教堂为逃亡者提供庇护，并帮助疏散和提供人道主义援助。&lt;/p>;&lt;p>;在乌克兰中部的第聂伯罗，在烛台中心周围的街道上可以看到从衣服上可以看出是东正教的家庭。设有犹太博物馆、犹太酒店、犹太商店和犹太教堂。穿着制服、穿着 kippah 的男人在外面抽烟。一些乌克兰犹太士兵在移民到以色列之前在乌克兰出生或长大。现在他们已经重返战场。&lt;/p>;&lt;p>;过去三十年来，乌克兰犹太人最不寻常的变化之一就是身份的变化。第二次世界大战后的几十年里，乌克兰的大多数犹太人都讲俄语，并被认为是苏联犹太人。现在，那些留下来的人被认为是乌克兰犹太人。犹太祈祷书首次被翻译成乌克兰语。 &lt;/p>;&lt;p>;在今天的乌克兰，俄罗斯人是敌人。人们越来越普遍地听到以色列这个被敌人包围的繁荣国家被视为乌克兰未来的典范。然而，尽管乌克兰的犹太人从未如此远离反犹太主义，但一种根深蒂固的恐惧仍然存在。有人认为，如果战争中出现严重问题，泽伦斯基的遗产可能会成​​为新的反犹太主义的避雷针，而犹太人将被指责为乌克兰的失败。他们祈祷胜利的又一个理由。&lt;span data-ornament=&quot;ufinish&quot;>;■&lt;/span>;&lt;/p>;</description><pubDate> Thu, 14 Sep 2023 02:27:03 +0800</pubDate> </item><item><title><![CDATA[Impulsive, pugnacious and self-destructive: a new book on Elon Musk | Culture]]></title><link/><![CDATA[https://www.economist.com/culture/2023/09/12/impulsive-and-self-destructive-elon-musk-as-depicted-in-a-new-book]]><description> &lt;img src=&quot;https://images.weserv.nl/?url=www.economist.com/img/b/1280/720/90/media-assets/image/20230916_CUP004.jpg&quot;/>;&lt;div>;&lt; /div>;&lt;p>;&lt;b>;埃隆·马斯克。&lt;/b>; 作者：沃尔特·艾萨克森。 &lt;i>;西蒙和舒斯特尔； 688 页； 35 美元和 28 英镑&lt;/i>;&lt;/p>;&lt;p data-caps=&quot;initial&quot;>;&lt;span data-caps=&quot;initial&quot;>;W&lt;/span>;&lt;small>;HAT EXACTLY&lt;/small>; 正在进行中埃隆·马斯克？这个问题曾经只困扰着技术人员。但马斯克在太空发射服务、卫星互联网接入、电动汽车和社交媒体领域的突出地位意味着，这位世界首富不可预测的行为现在已经对全球产生了影响。他控制着唐纳德·特朗普对推特的访问、乌克兰武装部队的互联网连接以及美国将人员送入太空的能力。他改变了多个行业的进程。而且他有一种发现未来重要事物的能力（因此他对大脑芯片和人形机器人的押注可能值得关注）。难怪现在有这么多人想知道马斯克先生的动力所在。&lt;/p>;&lt;div>;&lt;div>;&lt;div id=&quot;econ-1&quot;>;&lt;/div>;&lt;/div>;&lt;/div>;&lt;p>;沃尔特·艾萨克森在这本私密的传记中着手回答这个问题。他曾是史蒂夫·乔布斯的&lt;a href=&quot;https://www.economist.com/books-and-arts/2011/10/29/insanely-great&quot;>;传记作者&lt;/a>;，曾跟随马斯克先生两年，接触他的家人和最亲密的知己，绘制出详细的心理肖像。 &lt;/p>;&lt;p>;马斯克出生于 1971 年，在南非度过了一个动荡的童年。他部分是由一位苦苦挣扎的单亲母亲抚养长大的，部分是由一位虐待他的父亲抚养长大的。在学校受到暴力欺凌后，马斯克先生陷入了白日梦和科幻小说中小说&lt;/a>;。年轻时他移民，先是加拿大，然后是美国。他在 20 世纪 90 年代末的互联网热潮期间赚到了第一个数百万美元，与他人共同创立了一个在线商业目录，然后又创建了一家在线银行，合并后，&lt;a href=&quot;https://www.economist.com/culture/2022 /02/19/the-Founders-examines-the-rise-and-legend-of-paypal&quot;>;成为 PayPal&lt;/a>;。然后，他为自己设定了一个适度的目标，即将&lt;i>;智人&lt;/i>;变成一种能够在地球上灭绝的情况下幸存下来的“多行星物种”。&lt;/p>;&lt;p>;很难想象还有其他人能做到这一点他在许多不同的领域做出了令人震惊的改变，尤其是他的火箭公司 SpaceX 和电动汽车制造商特斯拉。然而，由于马斯克的政治言论、对“清醒病毒”的讨伐以及对 Twitter 的不稳定管理（出于某种原因，他将 Twitter 重新命名为“X”），马斯克受到了广泛的厌恶和钦佩。艾萨克森先生描述了一个对人类抱有崇高愿景的人，但他冲动、好斗且具有自我毁灭性。&lt;/p>;&lt;p>;在艾萨克森先生看来，马斯克先生坚信人类正在走向灾难。因此，他具有超人的职业道德（这个人几乎不睡觉）和对风险的容忍度（他多次危及自己的财富，并经常迫使他的工程师进行有计划的赌博）。因此，他也习惯于严厉斥责甚至立即解雇他认为不称职或不够忠诚的员工。 &lt;/p>;&lt;p>;&lt;iframe height=&quot;360&quot; src=&quot;https://www.youtube.com/embed/p3_35pxme44?enablejsapi=1&quot;>;&lt;/iframe>;&lt;/p>;&lt;p>;马斯克先生相信自己的智慧。当谈到人工智能时，他不相信任何人，但可以相信他会保护人类免受恶意机器的侵害。他也被卷入了地缘政治。艾萨克森先生讲述了&lt;a href=&quot;https://www.economist.com/briefing/2022/10/06/elon-musks-foray-into-geopolitics-has-ukraine-worried&quot;>;如何&lt;i>;去年 10 月《经济学人》报道，马斯克拒绝让乌克兰使用他的卫星互联网服务 Starlink 来攻击占领克里米亚的俄罗斯军队，因为担心对半岛的攻击可能会引发核报复。 （乌克兰后来对此进行了攻击，但没有引发这样的反应。）&lt;/p>;&lt;p>;出现的是这样一幅画面：一位有干劲、才华横溢的企业家，尽管他对全球事务的影响力不断增强，但他却变得越来越不稳定和狭隘。毫无疑问，其他商界领袖也有能力做出不可预测的行为——我想到了乔布斯（作者鼓励进行这样的比较）——但他们并没有在 Twitter 上实时表达自己的想法。马斯克被誉为乔布斯的继任者，现在人们将他与另一位善变的亿万富翁进行比较，这位亿万富翁激发了狂热的忠诚，同时又表现得像一个愤愤不平的小孩。 &lt;/p>;&lt;div>;&lt;div>;&lt;div id=&quot;econ-2&quot;>;&lt;/div>;&lt;/div>;&lt;/div>;&lt;p>;真正的马斯克先生是否已经出现，他的财富和权力越来越不受约束？是否已经增长，或者这种行为是否因他使用 Twitter 而加剧？可能两者兼而有之。艾萨克森承认他的拍摄对象有时会表现得很愚蠢。马斯克对社交媒体的沉迷引发了不必要的争吵。他指责泰国的一名救援潜水员是“恋童癖者”，引发了一场诽谤诉讼（马斯克胜诉）。他宣称自己有“资金保障”来将特斯拉私有化，但实际上他没有，并且不得不与美国证券交易委员会达成数百万美元的和解。正如马斯克承认的那样：“我经常搬起石头砸自己的脚，我应该买一些凯夫拉尔靴子。”近年来，他的推文猛烈抨击了左翼在性别认同等问题上的立场，并与右翼&lt;a href=&quot;https://www.economist.com/culture/2023/09/09/conspiracy-theorists-are-obsessed-with-the-rothschild-family&quot;>;阴谋论&lt;/一个>;。艾萨克森表示，这种右倾的部分原因是马斯克和他的跨性别女儿珍娜之间的争吵，珍娜的马克思主义世界观导致她与父亲断绝关系。马斯克认为 Twitter 已经感染了沃克瑞并正在审查另类观点，这是他决定购买 Twitter 的一个重要因素。艾萨克森先生还推测，这笔交易给了因童年欺凌而伤痕累累的马斯克先生一个“拥有游乐场”的机会。&lt;/p>;&lt;p>;现在所有这一切都有可能掩盖马斯克先生的积极贡献。一些特斯拉司机兜售保险杠贴纸，上面写着“在我们都知道埃隆是个混蛋之前我就买了这辆车”。更令人担忧的是，他似乎超出了地缘政治的深度。这本家门口大小的书扣人心弦地讲述了马斯克先生非凡的一生。但我们很难不感到埃隆·马斯克的故事还只讲了一半。 &lt;span data-ornament=&quot;ufinish&quot;>;■&lt;/span>;&lt;/p>;</description><pubDate> Wed, 13 Sep 2023 20:57:02 +0800</pubDate> </item><item><title><![CDATA[Why is Kim Jong Un in Russia? | News]]></title><link/><![CDATA[https://www.economist.com/news/2023/09/12/why-is-kim-jong-un-in-russia]]><description> &lt;img src=&quot;https://images.weserv.nl/?url=www.economist.com/img/b/1280/720/90/media-assets/image/20230916_PDP504.jpg&quot;/>;&lt;div>;&lt; /div>;&lt;p data-caps=&quot;initial&quot;>;&lt;span data-caps=&quot;initial&quot;>;我&lt;/span>;&lt;small>;这是一次罕见的&lt;/small>;隐士国家之外的旅行，看来独裁者正在计划会见弗拉基米尔·普京。武器交易的前景摆在桌面上，国际社会应该有多担心？ &lt;a href=&quot;https://www.economist.com/cities-are-suing-car-manufacturers-over-auto-theft-they-have-a-case&quot; data-tegid=&quot;4npm7t0i9fsvh9pnib2ja26c52n2jlgo&quot;>;汽车盗窃&lt; /a>; 在美国这是一个日益严重的问题，汽车制造商负有部分责任 (08:49)。法国的蓬勃发展&lt;a href=&quot;https://www.economist.com/europe/2023/08/17/french-bakeries-are-thriving-in-unlikely-places&quot; data-tegid=&quot;rcubkqtllcpi1v5av1ja7podfgeo5a15&quot;>;面包店&lt; /a>; (15:02)。运行时间：19 分钟&lt;/p>;&lt;p>;&lt;iframe height=&quot;215&quot; src=&quot;https://embed.acast.com/theintelligencepodcast/midnight-train-to-moscow-kim-jong-un-cosies-up -with-russia&quot;>;&lt;/iframe>;&lt;/p>;&lt;p>;Listen on: &lt;a href=&quot;https://www.economist.comhttps://podcasts.apple.com/us/podcast/the-intelligence -from-the-economist/id1449631195&quot;>;Apple Podcasts&lt;/a>; | &lt;a href=&quot;https://www.economist.comhttps://open.spotify.com/show/12zKAMNyS2GNentUzxq9QN&quot;>;Spotify&lt;/a>; | &lt;a href=&quot;https://www.economist.comhttps://podcasts.google.com/feed/aHR0cHM6Ly9mZWVkcy5hY2FzdC5jb20vcHVibGljL3Nob3dzL2Q1NTZlYjU0LTYxNjAtNGM4NS05NWY0LTQ3ZDlmNTIxNmM0OQ&quot;>;Google&lt;/a>; | &lt;a href=&quot;https://www.economist.comhttps://www.stitcher.com/s?fid=357733&amp;amp;%3Brefid=stpr&quot;>;Stitcher&lt;/a>; | &lt;a href=&quot;https://www.economist.comhttps://tunein.com/podcasts/News--Politics-Podcasts/The-Intelligence-p1186979/%20%22&quot;>;TuneIn&lt;/a>;&lt;/p>;&lt;p>;For full access to print, digital and audio editions of &lt;i>;The Economist&lt;/i>;, try a free 30-day digital subscription by going to &lt;a href=&quot;https://www.economist.comhttps://www.economist.com/intelligenceoffer&quot;>;www.economist.com/intelligenceoffer&lt;/a>;&lt;/p>;</description><pubDate> Wed, 13 Sep 2023 20:57:02 +0800</pubDate> </item><item><title><![CDATA[Why is Kim Jong Un in Russia? | Podcasts]]></title><link/><![CDATA[https://www.economist.com/podcasts/2023/09/12/why-is-kim-jong-un-in-russia]]><description> &lt;img src=&quot;https://images.weserv.nl/?url=www.economist.com/img/b/1280/720/90/media-assets/image/20230916_PDP504.jpg&quot;/>;&lt;div>;&lt;/div>;&lt;p data-caps=&quot;initial&quot;>;&lt;span data-caps=&quot;initial&quot;>;I&lt;/span>;&lt;small>;na rare&lt;/small>; trip outside of the hermit state, it seems the dictator is planning to meet with Vladimir Putin.武器交易的前景摆在桌面上，国际社会应该有多担心？ &lt;a href=&quot;https://www.economist.com/cities-are-suing-car-manufacturers-over-auto-theft-they-have-a-case&quot; data-tegid=&quot;4npm7t0i9fsvh9pnib2ja26c52n2jlgo&quot;>;Car theft&lt;/a>; is a growing problem in America and automakers are partly to blame (08:49). And France&#39;s booming &lt;a href=&quot;https://www.economist.com/europe/2023/08/17/french-bakeries-are-thriving-in-unlikely-places&quot; data-tegid=&quot;rcubkqtllcpi1v5av1ja7podfgeo5a15&quot;>;boulangeries&lt;/a>; (15:02). Runtime: 19 min&lt;/p>;&lt;p>;&lt;iframe height=&quot;215&quot; src=&quot;https://embed.acast.com/theintelligencepodcast/midnight-train-to-moscow-kim-jong-un-cosies-up-with-russia&quot;>;&lt;/iframe>;&lt;/p>;&lt;p>;Listen on: &lt;a href=&quot;https://www.economist.comhttps://podcasts.apple.com/us/podcast/the-intelligence-from-the-economist/id1449631195&quot;>;Apple Podcasts&lt;/a>; | &lt;a href=&quot;https://www.economist.comhttps://open.spotify.com/show/12zKAMNyS2GNentUzxq9QN&quot;>;Spotify&lt;/a>; | &lt;a href=&quot;https://www.economist.comhttps://podcasts.google.com/feed/aHR0cHM6Ly9mZWVkcy5hY2FzdC5jb20vcHVibGljL3Nob3dzL2Q1NTZlYjU0LTYxNjAtNGM4NS05NWY0LTQ3ZDlmNTIxNmM0OQ&quot;>;Google&lt;/a>; | &lt;a href=&quot;https://www.economist.comhttps://www.stitcher.com/s?fid=357733&amp;amp;%3Brefid=stpr&quot;>;Stitcher&lt;/a>; | &lt;a href=&quot;https://www.economist.comhttps://tunein.com/podcasts/News--Politics-Podcasts/The-Intelligence-p1186979/%20%22&quot;>;TuneIn&lt;/a>;&lt;/p>;&lt;p>;For full access to print, digital and audio editions of &lt;i>;The Economist&lt;/i>;, try a free 30-day digital subscription by going to &lt;a href=&quot;https://www.economist.comhttps://www.economist.com/intelligenceoffer&quot;>;www.economist.com/intelligenceoffer&lt;/a>;&lt;/p>;</description><pubDate> Wed, 13 Sep 2023 20:57:02 +0800</pubDate> </item><item><title><![CDATA[Why is China so outraged at the Fukushima wastewater release? | Podcasts]]></title><link/><![CDATA[https://www.economist.com/podcasts/2023/09/12/why-is-china-so-outraged-at-the-fukushima-wastewater-release]]><description> &lt;img src=&quot;https://images.weserv.nl/?url=www.economist.com/img/b/1280/720/90/media-assets/image/20230916_PDP505.jpg&quot;/>;&lt;div>;&lt;/div>;&lt;p data-caps=&quot;initial&quot;>;&lt;span data-caps=&quot;initial&quot;>;C&lt;/span>;&lt;small>;hinese social&lt;/small>; media is awash with disinformation about nuclear wastewater. Ever since August 24, when Japan began to release &lt;a href=&quot;https://www.economist.com/china/2023/08/30/china-is-stoking-anger-over-japans-release-of-nuclear-wastewater&quot;>;treated wastewate&lt;/a>;r from the Fukushima plant, China&#39;s state media has pumped out &lt;a href=&quot;https://www.economist.com/asia/2023/07/13/asia-is-rowing-about-fukushima-nuclear-wastewater&quot;>;a flood of one-sided reports about the dangers&lt;/a>;. China&#39;s nationalist netizens have spread them.&lt;/p>;&lt;p>;Alice Su, &lt;i>;The Economist&#39;&lt;/i>;s senior China correspondent, and Ted Plafker, our China correspondent, take a look inside a Chinese Communist Party disinformation campaign and ask what China&#39;s government stands to gain from the public outrage over the Fukushima wastewater release.&lt;/p>;&lt;p>;&lt;iframe height=&quot;215&quot; src=&quot;https://embed.acast.com/drumtower/drum-tower-nuclear-reaction&quot;>;&lt;/iframe>;&lt;/p>;&lt;p>;Sign up to our weekly newsletter &lt;a href=&quot;https://www.economist.com/china/2022/09/17/introducing-drum-tower-our-new-china-newsletter&quot;>;here&lt;/a>; and for full access to print, digital and audio editions, as well as exclusive live events, subscribe to The Economist at &lt;a href=&quot;https://www.economist.comhttps://www.economist.com/drumoffer&quot;>;economist.com/drumoffer&lt;/a>;.&lt;/p>;&lt;p>;Listen on: &lt;a href=&quot;https://www.economist.comhttps://podcasts.apple.com/us/podcast/drum-tower/id1651657142&quot;>;Apple Podcasts &lt;/a>; | &lt;a href=&quot;https://www.economist.comhttps://open.spotify.com/show/1UWf6NmSmpqcehsYGkcGjh?si=a72403a7f1d348f7&quot;>;Spotify&lt;/a>; | &lt;a href=&quot;https://www.economist.comhttps://podcasts.google.com/feed/aHR0cHM6Ly9mZWVkcy5hY2FzdC5jb20vcHVibGljL3Nob3dzL2RydW10b3dlcg&quot;>;Google&lt;/a>; | &lt;a href=&quot;https://www.economist.comhttps://feeds.acast.com/public/shows/633ebf6dfc7f5a0012acdc97&quot;>;RSS&lt;/a>;&lt;/p>;&lt;br>;&lt;hr>;&lt;div>;获取更多RSS：&lt;br>;&lt;a href=&quot;https://feedx.net&quot; style=&quot;color:orange&quot; target=&quot;_blank&quot;>;https://feedx.net&lt;/a>; &lt;br>;&lt;a href=&quot;https://feedx.best&quot; style=&quot;color:orange&quot; target=&quot;_blank&quot;>;https://feedx.best&lt;/a>;&lt;br>;&lt;/div>;</description><pubDate> Wed, 13 Sep 2023 20:57:02 +0800</pubDate> </item><item><title><![CDATA[How to escape from prison | The Economist explains]]></title><link/><![CDATA[https://www.economist.com/the-economist-explains/2023/09/11/how-to-escape-from-prison]]><description> &lt;img src=&quot;https://images.weserv.nl/?url=www.economist.com/img/b/1280/720/90/media-assets/image/20230916_BLP501.jpg&quot;/>;&lt;div>;&lt;/div>;&lt;p data-caps=&quot;initial&quot;>;&lt;span data-caps=&quot;initial&quot;>;D&lt;/span>;&lt;small>;ANIEL KHALIFE&lt;/small>;, a suspected terrorist, enjoyed about 75 hours of freedom after escaping from &lt;small>;HMP&lt;/small>; Wandsworth, in south-west London, on September 6th. Three days later a police officer pulled him from a bike in north-west London. On September 11th he was charged with escaping custody. The court was told that Mr Khalife may have used sheets to tie himself to the undercarriage of a van leaving the prison.&lt;/p>;&lt;p>;Prison breaks in Britain have &lt;a href=&quot;https://www.economist.com/britain/2023/09/08/the-escape-of-a-terror-suspect-shines-a-light-on-britains-jails&quot;>;fallen precipitously&lt;/a>; since the 1990s. This is largely the result of new technology, such as scanners at gates, and cameras covering every corner of the prison estate, whose displays are permanently monitored from central control rooms. Probable candidates for escape bids are made to wear blue and yellow harlequin-style outfits. Yet despite all this, as Mr Khalife showed, audacious escapes are still possible. How?&lt;/p>;&lt;div>;&lt;div>;&lt;div id=&quot;econ-1&quot;>;&lt;/div>;&lt;/div>;&lt;/div>;&lt;p>;Prison breaks depend on ingenuity. In 1980 a new wing opened in &lt;small>;HMP&lt;/small>; Brixton, close to Wandsworth, to house the prison&#39;s most dangerous criminals. To test its security, a team of specialist soldiers was challenged to break out. But although they failed, three prisoners would succeed.&lt;/p>;&lt;p>;The trio were not obvious accomplices. Gerard Tuite was a member of the &lt;small>;IRA&lt;/small>;. James “Big Jim” Moody and Stanley Thompson were bank robbers. They tunnelled between their adjoining cells using a drill fashioned from a table leg, a broom head and a radiator cap. They applied paint, cardboard and tape to hide the damage to the 17-inch-thick walls. Then, in December 1980, they ascended the perimeter wall with the help of some scaffolding that was being used to make repairs, having left dummies in their beds. Scaling prison walls takes daring, but can pay off: in 1966 George Blake, a Soviet spy, escaped from &lt;small>;HMP&lt;/small>; Wormwood Scrubs, in west London, using a ladder made of knitting needles.&lt;/p>;&lt;p>;Help from the outside is often essential. Tuite, Moody and Thompson had accomplices smuggle in drill bits, hacksaw blades and screwdrivers. In 1991 Pearse McAuley and Nessan Quinlivan, two other members of the &lt;small>;IRA&lt;/small>;, shot their way out of &lt;small>;HMP&lt;/small>; Brixton using a gun that had been hidden in the sole of a shoe posted to the prison from Ireland. In 1999 John Kendall, a gangland boss, and Sydney Draper, a murderer, flew out of &lt;small>;HMP&lt;/small>; Gartree in Leicestershire in a helicopter that had been hijacked by an accomplice.&lt;/p>;&lt;p>;It is not yet clear whether Mr Khalife had any outside help. But he does seem to have been aided by his circumstances. As a terror suspect, he would seem to have been eligible for incarceration at &lt;small>;HMP&lt;/small>; Belmarsh, a prison in south-east London with higher security than Wandsworth, where many prisoners awaiting trial in London are held. At the time of his escape he was working in the prison kitchens, where frequent deliveries from the outside world are received. That suggests he was not seen as a flight risk.&lt;/p>;&lt;div>;&lt;div>;&lt;div id=&quot;econ-2&quot;>;&lt;/div>;&lt;/div>;&lt;/div>;&lt;p>;Prison authorities get wiser with each attempted escape. But they are hampered by the age of their estate and staffing shortages. The 172-year-old &lt;small>;HMP&lt;/small>; Wandsworth holds some 1,600 prisoners but staff absences are high. Inspectors have said that this is the source of many problems at the “crumbling” and overcrowded prison.&lt;/p>;&lt;p>;Alex Chalk, Britain&#39;s justice secretary, has said that the relevant security positions were staffed on the day of Mr Khalife&#39;s escape. The issue, therefore, is whether proper procedures were followed: vans are normally thoroughly checked when leaving prisons. An investigation may uncover worrying results. Still, as Mr Khalife might attest, escape counts for little if it lasts for less than four days.&lt;span data-ornament=&quot;ufinish&quot;>;■&lt;/span>;&lt;/p>;</description><pubDate> Wed, 13 Sep 2023 08:57:02 +0800</pubDate> </item><item><title><![CDATA[The ethical drug-dealers of Vancouver | 1843 magazine]]></title><link/><![CDATA[https://www.economist.com/1843/2023/09/08/the-ethical-drug-dealers-of-vancouver]]><description> &lt;img src=&quot;https://images.weserv.nl/?url=www.economist.com/img/b/1846/1037/90/media-assets/image/1843_20230912_1843_DRUGS_TEASER.jpg&quot;/>;&lt;div>;&lt;/div>;&lt;p data-caps=&quot;initial&quot;>;&lt;span data-caps=&quot;initial&quot;>;O&lt;/span>;na hot Sunday in July&lt;b>;, &lt;/b>;a woman in her late 30s called Phoenix entered an unmarked shop in downtown Vancouver and approached the counter. “I&#39;ll have a half gram of cocaine, please,” she said. The proprietor scanned a barcode: C$33 (around $24.50), a bargain for the drug at this purity. The packaging promised unadulterated coke – “no cut/no buff” – above a warning that the product is highly addictive, may impair driving ability and should be kept away from children and pets. &lt;/p>;&lt;p>;Phoenix then gathered complimentary supplies from across the room: syringes, needles, paper filters, tissues and a small cooking spoon. She carried them to a sanitised metal table, where she liquefied and mixed the cocaine with &lt;a href=&quot;https://www.economist.com/united-states/2023/07/27/fentanyl-is-spreading-the-opioid-crisis-into-americas-big-cities&quot;>;fentanyl – a powerful synthetic opioid&lt;/a>; she had bought from her usual dealer – to create the rush she wanted, and drew the solution into a syringe. She jumped up and down, twirling an invisible skipping rope to improve her blood flow. Then she sat down, inserted a needle above the knuckle of her index finger and injected.&lt;/p>;&lt;p>;&lt;cite>;The packaging promised unadulterated coke – “no cut/no buff” – above a warning that the product is highly addictive, may impair driving ability and should be kept away from children and pets&lt;/cite>;&lt;/p>;&lt;p>;Eris Nyx, one of the store&#39;s managers, looked on from the cash point. She runs the shop with Jeremy Kalicum, who was in the back office weighing and packaging cocaine, heroin and methamphetamine. “The fact that we&#39;re not in jail is unbelievable,” said Eris. “I think about that every day.” &lt;/p>;&lt;p>;In 2015, Eris was working at a bike-repair shop when she heard that staff at a nearby homeless shelter made twice her wage. She quit to pick up shifts there instead. The next year, the province of British Columbia, where Vancouver is located, declared a public health emergency. People were dying in large numbers from street drugs tainted with fentanyl, which mimicked the effects of heroin at a fraction of the price but could be fatal even at small doses. Eris observed the drug&#39;s prevalence amongst the shelter&#39;s residents: “You&#39;d have ten overdoses on your shift,” she said. Nearly a thousand people died of overdoses in the province that year, often by contaminated street drugs. Within five years, more than twice as many were dying annually. &lt;/p>;&lt;figure>;&lt;span itemscope=&quot;&quot; itemProp=&quot;image&quot; itemType=&quot;https://schema.org/ImageObject&quot;>;&lt;meta itemProp=&quot;url&quot; content=&quot;https://www.economist.com/img/b/1263/843/90/media-assets/image/1843_20230908_1843_DRUGS_02.jpg&quot;/>;&lt;img loading=&quot;lazy&quot; width=&quot;1263&quot; height=&quot;843&quot; src=&quot;https://www.economist.com/img/b/1263/843/90/media-assets/image/1843_20230908_1843_DRUGS_02.jpg&quot; srcSet=&quot;https://www.economist.com/img/b/200/133/90/media-assets/image/1843_20230908_1843_DRUGS_02.jpg 200w,https://www.economist.com/img/b/300/200/90/media-assets/image/1843_20230908_1843_DRUGS_02.jpg 300w,https://www.economist.com/img/b/400/267/90/media-assets/image/1843_20230908_1843_DRUGS_02.jpg 400w,https://www.economist.com/img/b/600/400/90/media-assets/image/1843_20230908_1843_DRUGS_02.jpg 600w,https://www.economist.com/img/b/640/427/90/media-assets/image/1843_20230908_1843_DRUGS_02.jpg 640w,https://www.economist.com/img/b/800/534/90/media-assets/image/1843_20230908_1843_DRUGS_02.jpg 800w,https://www.economist.com/img/b/1000/667/90/media-assets/image/1843_20230908_1843_DRUGS_02.jpg 1000w,https://www.economist.com/img/b/1280/854/90/media-assets/image/1843_20230908_1843_DRUGS_02.jpg 1280w&quot; sizes=&quot;(min-width: 720px) 640px, 95vw&quot; alt=&quot;&quot;/>;&lt;/span>;&lt;/figure>;&lt;figure>;&lt;span itemscope=&quot;&quot; itemProp=&quot;image&quot; itemType=&quot;https://schema.org/ImageObject&quot;>;&lt;meta itemProp=&quot;url&quot; content=&quot;https://www.economist.com/img/b/1432/1943/90/media-assets/image/1843_20230908_1843_DRUGS_03.jpg&quot;/>;&lt;img loading=&quot;lazy&quot; width=&quot;1432&quot; height=&quot;1943&quot; src=&quot;https://www.economist.com/img/b/1432/1943/90/media-assets/image/1843_20230908_1843_DRUGS_03.jpg&quot; srcSet=&quot;https://www.economist.com/img/b/200/271/90/media-assets/image/1843_20230908_1843_DRUGS_03.jpg 200w,https://www.economist.com/img/b/300/407/90/media-assets/image/1843_20230908_1843_DRUGS_03.jpg 300w,https://www.economist.com/img/b/400/543/90/media-assets/image/1843_20230908_1843_DRUGS_03.jpg 400w,https://www.economist.com/img/b/600/814/90/media-assets/image/1843_20230908_1843_DRUGS_03.jpg 600w,https://www.economist.com/img/b/640/868/90/media-assets/image/1843_20230908_1843_DRUGS_03.jpg 640w,https://www.economist.com/img/b/800/1085/90/media-assets/image/1843_20230908_1843_DRUGS_03.jpg 800w,https://www.economist.com/img/b/1000/1357/90/media-assets/image/1843_20230908_1843_DRUGS_03.jpg 1000w,https://www.economist.com/img/b/1280/1737/90/media-assets/image/1843_20230908_1843_DRUGS_03.jpg 1280w&quot; sizes=&quot;(min-width: 720px) 640px, 95vw&quot; alt=&quot;&quot;/>;&lt;/span>;&lt;/figure>;&lt;figure>;&lt;span itemscope=&quot;&quot; itemProp=&quot;image&quot; itemType=&quot;https://schema.org/ImageObject&quot;>;&lt;meta itemProp=&quot;url&quot; content=&quot;https://www.economist.com/img/b/1263/843/90/media-assets/image/1843_20230908_1843_DRUGS_04.jpg&quot;/>;&lt;img loading=&quot;lazy&quot; width=&quot;1263&quot; height=&quot;843&quot; src=&quot;https://www.economist.com/img/b/1263/843/90/media-assets/image/1843_20230908_1843_DRUGS_04.jpg&quot; srcSet=&quot;https://www.economist.com/img/b/200/133/90/media-assets/image/1843_20230908_1843_DRUGS_04.jpg 200w,https://www.economist.com/img/b/300/200/90/media-assets/image/1843_20230908_1843_DRUGS_04.jpg 300w,https://www.economist.com/img/b/400/267/90/media-assets/image/1843_20230908_1843_DRUGS_04.jpg 400w,https://www.economist.com/img/b/600/400/90/media-assets/image/1843_20230908_1843_DRUGS_04.jpg 600w,https://www.economist.com/img/b/640/427/90/media-assets/image/1843_20230908_1843_DRUGS_04.jpg 640w,https://www.economist.com/img/b/800/534/90/media-assets/image/1843_20230908_1843_DRUGS_04.jpg 800w,https://www.economist.com/img/b/1000/667/90/media-assets/image/1843_20230908_1843_DRUGS_04.jpg 1000w,https://www.economist.com/img/b/1280/854/90/media-assets/image/1843_20230908_1843_DRUGS_04.jpg 1280w&quot; sizes=&quot;(min-width: 720px) 640px, 95vw&quot; alt=&quot;&quot;/>;&lt;/span>;&lt;figcaption>;&lt;b>;Vancouver buyers club &lt;/b>;&lt;i>;Opening image &lt;/i>;Eris Nyx, co-founder of the Drug User Liberation Front (DULF), inventories drugs at the organisation&#39;s shop in Vancouver. A participant of the programme prepares to inject drugs (&lt;i>;top and middle&lt;/i>;). Eris (&lt;i>;left&lt;/i>;) with Jeremy Kalicum (&lt;i>;right&lt;/i>;) the other founder of the DULF (&lt;i>;bottom&lt;/i>;)&lt;/figcaption>;&lt;/figure>;&lt;p>;In response, a university-affiliated, government-funded research network called the British Columbia Centre on Substance Use proposed a plan for a “heroin compassion club”. It was modelled on buyers&#39; collectives that were formed during the &lt;small>;AIDS&lt;/small>; crisis decades earlier – when patients pooled funds to acquire medicinal cannabis (to ease some of the symptoms) and as-yet unapproved medications. Today, Canadian heroin users can sometimes get opioid alternatives like hydromorphone from health-care providers. But many of the most vulnerable aren&#39;t ready to submit to the programme&#39;s requirements for supervision and emphasis on abstinence. Those that do engage often find it physically difficult to switch from their usual supply to prescribed replacements. &lt;/p>;&lt;p>;&lt;cite>;“The fact that we&#39;re not in jail is unbelievable,” said Eris. “I think about that every day”&lt;/cite>;&lt;/p>;&lt;p>;A growing movement among social workers and health-care professionals wants drug policy to focus less on interventionist measures and punishment and more on what&#39;s called harm reduction, which aims to mitigate the negative physical and social consequences of addiction. The logical conclusion of harm reduction, some believe, is an affordable, accessible store for hard drugs. “Safe supply has to be as easy as calling your guy and getting the thing you want for the price you&#39;re willing to pay,” said Phoenix, who is a regular at the shop and asked only to be identified by her first name. The drug store run by the Drug User Liberation Front (&lt;small>;DULF&lt;/small>;) – as Eris and Jeremy have named their initiative – has been running for a year. No customer has yet died of an overdose.&lt;/p>;&lt;div>;&lt;div>;&lt;div id=&quot;econ-1&quot;>;&lt;/div>;&lt;/div>;&lt;/div>;&lt;p data-caps=&quot;initial&quot;>;&lt;span data-caps=&quot;initial&quot;>;E&lt;/span>;ris, 32, is dazzlingly fluent, to the point of sometimes being glib and unfiltered. She alluded to a difficult home life growing up, but groaned at any suggestion that it explains why she got into this work. “I think if you see the things I&#39;ve seen, you would be doing the same thing,” she said of the drug crisis in Vancouver. “I open my front door and there&#39;s dead people all over the street.” She met Jeremy while planning a safe-supply conference in 2019, the year the heroin-compassion-club report came out. “At that conference, we were like, &#39;Somebody better step up and do this,&#39;” Eris said. Both are matter-of-fact about how they came to be those somebodies&lt;b>;. &lt;/b>;Jeremy, a wry and comparatively reserved 28-year-old, told me that, before starting &lt;small>;DULF&lt;/small>;, he planned on becoming a doctor. “I showed a lot of promise,” he joked. His career in harm reduction began when he volunteered at a needle-exchange programme to bolster future medical-school applications. (He still hopes to take the admissions exam.)&lt;/p>;&lt;figure>;&lt;span itemscope=&quot;&quot; itemProp=&quot;image&quot; itemType=&quot;https://schema.org/ImageObject&quot;>;&lt;meta itemProp=&quot;url&quot; content=&quot;https://www.economist.com/img/b/1263/843/90/media-assets/image/1843_20230908_1843_DRUGS_05.jpg&quot;/>;&lt;img loading=&quot;lazy&quot; width=&quot;1263&quot; height=&quot;843&quot; src=&quot;https://www.economist.com/img/b/1263/843/90/media-assets/image/1843_20230908_1843_DRUGS_05.jpg&quot; srcSet=&quot;https://www.economist.com/img/b/200/133/90/media-assets/image/1843_20230908_1843_DRUGS_05.jpg 200w,https://www.economist.com/img/b/300/200/90/media-assets/image/1843_20230908_1843_DRUGS_05.jpg 300w,https://www.economist.com/img/b/400/267/90/media-assets/image/1843_20230908_1843_DRUGS_05.jpg 400w,https://www.economist.com/img/b/600/400/90/media-assets/image/1843_20230908_1843_DRUGS_05.jpg 600w,https://www.economist.com/img/b/640/427/90/media-assets/image/1843_20230908_1843_DRUGS_05.jpg 640w,https://www.economist.com/img/b/800/534/90/media-assets/image/1843_20230908_1843_DRUGS_05.jpg 800w,https://www.economist.com/img/b/1000/667/90/media-assets/image/1843_20230908_1843_DRUGS_05.jpg 1000w,https://www.economist.com/img/b/1280/854/90/media-assets/image/1843_20230908_1843_DRUGS_05.jpg 1280w&quot; sizes=&quot;(min-width: 720px) 640px, 95vw&quot; alt=&quot;&quot;/>;&lt;/span>;&lt;/figure>;&lt;figure>;&lt;span itemscope=&quot;&quot; itemProp=&quot;image&quot; itemType=&quot;https://schema.org/ImageObject&quot;>;&lt;meta itemProp=&quot;url&quot; content=&quot;https://www.economist.com/img/b/1263/843/90/media-assets/image/1843_20230908_1843_DRUGS_06.jpg&quot;/>;&lt;img loading=&quot;lazy&quot; width=&quot;1263&quot; height=&quot;843&quot; src=&quot;https://www.economist.com/img/b/1263/843/90/media-assets/image/1843_20230908_1843_DRUGS_06.jpg&quot; srcSet=&quot;https://www.economist.com/img/b/200/133/90/media-assets/image/1843_20230908_1843_DRUGS_06.jpg 200w,https://www.economist.com/img/b/300/200/90/media-assets/image/1843_20230908_1843_DRUGS_06.jpg 300w,https://www.economist.com/img/b/400/267/90/media-assets/image/1843_20230908_1843_DRUGS_06.jpg 400w,https://www.economist.com/img/b/600/400/90/media-assets/image/1843_20230908_1843_DRUGS_06.jpg 600w,https://www.economist.com/img/b/640/427/90/media-assets/image/1843_20230908_1843_DRUGS_06.jpg 640w,https://www.economist.com/img/b/800/534/90/media-assets/image/1843_20230908_1843_DRUGS_06.jpg 800w,https://www.economist.com/img/b/1000/667/90/media-assets/image/1843_20230908_1843_DRUGS_06.jpg 1000w,https://www.economist.com/img/b/1280/854/90/media-assets/image/1843_20230908_1843_DRUGS_06.jpg 1280w&quot; sizes=&quot;(min-width: 720px) 640px, 95vw&quot; alt=&quot;&quot;/>;&lt;/span>;&lt;/figure>;&lt;figure>;&lt;span itemscope=&quot;&quot; itemProp=&quot;image&quot; itemType=&quot;https://schema.org/ImageObject&quot;>;&lt;meta itemProp=&quot;url&quot; content=&quot;https://www.economist.com/img/b/1382/922/90/media-assets/image/1843_20230908_1843_DRUGS_07.jpg&quot;/>;&lt;img loading=&quot;lazy&quot; width=&quot;1382&quot; height=&quot;922&quot; src=&quot;https://www.economist.com/img/b/1382/922/90/media-assets/image/1843_20230908_1843_DRUGS_07.jpg&quot; srcSet=&quot;https://www.economist.com/img/b/200/133/90/media-assets/image/1843_20230908_1843_DRUGS_07.jpg 200w,https://www.economist.com/img/b/300/200/90/media-assets/image/1843_20230908_1843_DRUGS_07.jpg 300w,https://www.economist.com/img/b/400/267/90/media-assets/image/1843_20230908_1843_DRUGS_07.jpg 400w,https://www.economist.com/img/b/600/400/90/media-assets/image/1843_20230908_1843_DRUGS_07.jpg 600w,https://www.economist.com/img/b/640/427/90/media-assets/image/1843_20230908_1843_DRUGS_07.jpg 640w,https://www.economist.com/img/b/800/534/90/media-assets/image/1843_20230908_1843_DRUGS_07.jpg 800w,https://www.economist.com/img/b/1000/667/90/media-assets/image/1843_20230908_1843_DRUGS_07.jpg 1000w,https://www.economist.com/img/b/1280/854/90/media-assets/image/1843_20230908_1843_DRUGS_07.jpg 1280w&quot; sizes=&quot;(min-width: 720px) 640px, 95vw&quot; alt=&quot;&quot;/>;&lt;/span>;&lt;/figure>;&lt;figure>;&lt;span itemscope=&quot;&quot; itemProp=&quot;image&quot; itemType=&quot;https://schema.org/ImageObject&quot;>;&lt;meta itemProp=&quot;url&quot; content=&quot;https://www.economist.com/img/b/1791/1194/90/media-assets/image/1843_20230908_1843_DRUGS_08.jpg&quot;/>;&lt;img loading=&quot;lazy&quot; width=&quot;1791&quot; height=&quot;1194&quot; src=&quot;https://www.economist.com/img/b/1791/1194/90/media-assets/image/1843_20230908_1843_DRUGS_08.jpg&quot; srcSet=&quot;https://www.economist.com/img/b/200/133/90/media-assets/image/1843_20230908_1843_DRUGS_08.jpg 200w,https://www.economist.com/img/b/300/200/90/media-assets/image/1843_20230908_1843_DRUGS_08.jpg 300w,https://www.economist.com/img/b/400/267/90/media-assets/image/1843_20230908_1843_DRUGS_08.jpg 400w,https://www.economist.com/img/b/600/400/90/media-assets/image/1843_20230908_1843_DRUGS_08.jpg 600w,https://www.economist.com/img/b/640/427/90/media-assets/image/1843_20230908_1843_DRUGS_08.jpg 640w,https://www.economist.com/img/b/800/533/90/media-assets/image/1843_20230908_1843_DRUGS_08.jpg 800w,https://www.economist.com/img/b/1000/667/90/media-assets/image/1843_20230908_1843_DRUGS_08.jpg 1000w,https://www.economist.com/img/b/1280/853/90/media-assets/image/1843_20230908_1843_DRUGS_08.jpg 1280w&quot; sizes=&quot;(min-width: 720px) 640px, 95vw&quot; alt=&quot;&quot;/>;&lt;/span>;&lt;figcaption>;&lt;b>;Secret stash &lt;/b>;The packages of meth, cocaine and heroin are held securely in a safe (&lt;i>;top&lt;/i>;). The pair met in 2019 (&lt;i>;second from top&lt;/i>;). Jeremy weighs and packages the drugs (&lt;i>;second from bottom and bottom&lt;/i>;) &lt;/figcaption>;&lt;/figure>;&lt;p>;Their shop was the culmination of a long experiment: how flagrantly could they traffic clean drugs without going to jail? At one of &lt;small>;DULF&lt;/small>;&#39;s early events, in the summer of 2021, they gave away free drugs in a police-station car park. Officers allowed the event to carry on. A sympathetic city councillor spoke to the gathered crowd about the need for a safer supply. Eris, dressed as Willy Wonka, stood beside her, cradling packages of meth, heroin and cocaine and grinning for the cameras. &lt;/p>;&lt;p>;Each month, on the day the province announced the latest overdose statistics – which were dire as ever – they would stage another giveaway. But media coverage dwindled over time. The press “want escalation”, Eris said. “They&#39;re like, come back to us when you&#39;re going to overdose in city hall or something.” &lt;/p>;&lt;p>;&lt;cite>;The drug store run by the Drug User Liberation Front has been running for a year. No customer has yet died of an overdose&lt;/cite>;&lt;/p>;&lt;p>;&lt;small>;DULF&lt;/small>; did step things up. They applied to the Canadian government for a legal exemption to procure pharmaceutical supplies of illicit narcotics and test, package and sell them, at cost, to customers in a shop. They had letters of support from doctors, addiction researchers, local politicians and the regional health authority.&lt;!-- -->; In July 2022 Canada&#39;s federal health department rejected their request. The next month, Eris and Jeremy opened the shop anyway. &lt;/p>;&lt;p data-caps=&quot;initial&quot;>;&lt;span data-caps=&quot;initial&quot;>;D&lt;/span>;ULF&#39;s store operates out of a secret location in Vancouver&#39;s downtown eastside. The neighbourhood is relatively untouched by gentrification, and homelessness and drug use is apparent on the sidewalks. Eris and Jeremy are not aware of anyone else in the world doing exactly what they do – at least not as publicly – so they&#39;ve had to devise a bespoke set of best practices. They took membership applications from would-be customers, and accepted a small group who were at high risk of overdose and were already known to existing drug-user groups – given the amount of work involved, 50 members felt like their maximum capacity. Each member participates in follow-up surveys with &lt;small>;DULF&lt;/small>; about how the shop has changed their health and habits; researchers from the Centre on Substance Use, the group that first proposed the heroin compassion club, are helping to collate that data. (Outcomes so far appear to be positive, but data are limited given the small number of participants.) With the help of volunteers, Eris and Jeremy keep a careful count of cash and inventory. Drugs are marked with test reference numbers and stored in a time-delayed safe; this protects against robbery by remaining locked until several minutes after entering the code, which only Eris and Jeremy know. Confidential member information is kept off-site. &lt;/p>;&lt;figure>;&lt;span itemscope=&quot;&quot; itemProp=&quot;image&quot; itemType=&quot;https://schema.org/ImageObject&quot;>;&lt;meta itemProp=&quot;url&quot; content=&quot;https://www.economist.com/img/b/1396/931/90/media-assets/image/1843_20230908_1843_DRUGS_09.jpg&quot;/>;&lt;img loading=&quot;lazy&quot; width=&quot;1396&quot; height=&quot;931&quot; src=&quot;https://www.economist.com/img/b/1396/931/90/media-assets/image/1843_20230908_1843_DRUGS_09.jpg&quot; srcSet=&quot;https://www.economist.com/img/b/200/133/90/media-assets/image/1843_20230908_1843_DRUGS_09.jpg 200w,https://www.economist.com/img/b/300/200/90/media-assets/image/1843_20230908_1843_DRUGS_09.jpg 300w,https://www.economist.com/img/b/400/267/90/media-assets/image/1843_20230908_1843_DRUGS_09.jpg 400w,https://www.economist.com/img/b/600/400/90/media-assets/image/1843_20230908_1843_DRUGS_09.jpg 600w,https://www.economist.com/img/b/640/427/90/media-assets/image/1843_20230908_1843_DRUGS_09.jpg 640w,https://www.economist.com/img/b/800/534/90/media-assets/image/1843_20230908_1843_DRUGS_09.jpg 800w,https://www.economist.com/img/b/1000/667/90/media-assets/image/1843_20230908_1843_DRUGS_09.jpg 1000w,https://www.economist.com/img/b/1280/854/90/media-assets/image/1843_20230908_1843_DRUGS_09.jpg 1280w&quot; sizes=&quot;(min-width: 720px) 640px, 95vw&quot; alt=&quot;&quot;/>;&lt;/span>;&lt;/figure>;&lt;figure>;&lt;span itemscope=&quot;&quot; itemProp=&quot;image&quot; itemType=&quot;https://schema.org/ImageObject&quot;>;&lt;meta itemProp=&quot;url&quot; content=&quot;https://www.economist.com/img/b/1078/1468/90/media-assets/image/1843_20230908_1843_DRUGS_10.jpg&quot;/>;&lt;img loading=&quot;lazy&quot; width=&quot;1078&quot; height=&quot;1468&quot; src=&quot;https://www.economist.com/img/b/1078/1468/90/media-assets/image/1843_20230908_1843_DRUGS_10.jpg&quot; srcSet=&quot;https://www.economist.com/img/b/200/272/90/media-assets/image/1843_20230908_1843_DRUGS_10.jpg 200w,https://www.economist.com/img/b/300/409/90/media-assets/image/1843_20230908_1843_DRUGS_10.jpg 300w,https://www.economist.com/img/b/400/545/90/media-assets/image/1843_20230908_1843_DRUGS_10.jpg 400w,https://www.economist.com/img/b/600/817/90/media-assets/image/1843_20230908_1843_DRUGS_10.jpg 600w,https://www.economist.com/img/b/640/872/90/media-assets/image/1843_20230908_1843_DRUGS_10.jpg 640w,https://www.economist.com/img/b/800/1089/90/media-assets/image/1843_20230908_1843_DRUGS_10.jpg 800w,https://www.economist.com/img/b/1000/1362/90/media-assets/image/1843_20230908_1843_DRUGS_10.jpg 1000w,https://www.economist.com/img/b/1280/1743/90/media-assets/image/1843_20230908_1843_DRUGS_10.jpg 1280w&quot; sizes=&quot;(min-width: 720px) 640px, 95vw&quot; alt=&quot;&quot;/>;&lt;/span>;&lt;/figure>;&lt;figure>;&lt;span itemscope=&quot;&quot; itemProp=&quot;image&quot; itemType=&quot;https://schema.org/ImageObject&quot;>;&lt;meta itemProp=&quot;url&quot; content=&quot;https://www.economist.com/img/b/1280/853/90/media-assets/image/1843_20230908_1843_DRUGS_11.jpg&quot;/>;&lt;img loading=&quot;lazy&quot; width=&quot;1280&quot; height=&quot;853&quot; src=&quot;https://www.economist.com/img/b/1280/853/90/media-assets/image/1843_20230908_1843_DRUGS_11.jpg&quot; srcSet=&quot;https://www.economist.com/img/b/200/133/90/media-assets/image/1843_20230908_1843_DRUGS_11.jpg 200w,https://www.economist.com/img/b/300/200/90/media-assets/image/1843_20230908_1843_DRUGS_11.jpg 300w,https://www.economist.com/img/b/400/267/90/media-assets/image/1843_20230908_1843_DRUGS_11.jpg 400w,https://www.economist.com/img/b/600/400/90/media-assets/image/1843_20230908_1843_DRUGS_11.jpg 600w,https://www.economist.com/img/b/640/427/90/media-assets/image/1843_20230908_1843_DRUGS_11.jpg 640w,https://www.economist.com/img/b/800/533/90/media-assets/image/1843_20230908_1843_DRUGS_11.jpg 800w,https://www.economist.com/img/b/1000/666/90/media-assets/image/1843_20230908_1843_DRUGS_11.jpg 1000w,https://www.economist.com/img/b/1280/853/90/media-assets/image/1843_20230908_1843_DRUGS_11.jpg 1280w&quot; sizes=&quot;(min-width: 720px) 640px, 95vw&quot; alt=&quot;&quot;/>;&lt;/span>;&lt;figcaption>;&lt;b>;Highs and lows &lt;/b>;Garth Mullins, an organiser with the Vancouver Area Network of Drug Users (VANDU). (&lt;i>;top&lt;/i>;). Notes from a VANDU meeting (&lt;i>;middle&lt;/i>;). The organisation is a user-led advocacy group that was founded in the late 1990s (&lt;i>;bottom&lt;/i>;)&lt;/figcaption>;&lt;/figure>;&lt;p>;Police have made few public statements about &lt;small>;DULF&lt;/small>;. Jeremy said he&#39;s had conversations with officers, who tell him the shop is “not a priority” for enforcement. Inspector Philip Heard of the Vancouver Police Department&#39;s organised crime unit confirmed those conversations in an interview with me. “I fully appreciate their rationale and where their heart is,” he said, but warned that “if someone is doing something that they know runs afoul of the law, then they will always potentially be the subject of enforcement.” The police have taken an inconsistent approach towards unofficial “safe supply” initiatives. In May they arrested 51-year-old Jerry Martin for trying to sell purity-tested drugs out of a trailer in the same neighbourhood; &lt;small>;DULF&lt;/small>;&#39;s shop, in contrast, remains open. (Tragically, Martin died two months later from a suspected fentanyl overdose.)&lt;/p>;&lt;div>;&lt;div>;&lt;div id=&quot;econ-2&quot;>;&lt;/div>;&lt;/div>;&lt;/div>;&lt;p>;Garth Mullins is an organiser with the Vancouver Area Network of Drug Users (&lt;small>;VANDU&lt;/small>;), a user-led advocacy group that was founded in the late 1990s and that helped found &lt;small>;DULF&lt;/small>;. “What &lt;small>;DULF&lt;/small>; does is illegal, and we know that, and the police know it,” he said, yet “nobody&#39;s been arrested because we&#39;ve built such a huge group of people around it.” &lt;small>;DULF&lt;/small>; is funded by the regional health authority as an overdose-prevention site, and by the Centre on Substance Use as a research project. A facility at the University of Victoria tests its substances. The shop has received drug-law exemptions for all these measures, except the essential bit: the buying and selling. “What&#39;s crazy is the fact that we run a fucking heroin store with quasi-sanctioning, with all these letters that are like, you can do X, Y and Z, but don&#39;t break the law,” said Eris. “It&#39;s enough of an exemption that if you ended up in court, it&#39;ll be a pretty kooky case.” &lt;/p>;&lt;p>;&lt;cite>;Their shop was the culmination of a long experiment: how flagrantly could they traffic clean drugs without going to jail?&lt;/cite>;&lt;/p>;&lt;p>;Despite the summer heat, Eris was wearing thick boots, heavy camo trousers and jacket, and an army-green &lt;small>;T&lt;/small>;-shirt when we met. It was not a subtle statement for&lt;!-- -->; an organisation with “liberation front” in its name. As a pair, Eris and Jeremy are difficult to categorise – they&#39;re scientists, they insisted, not drug-dealers. “We&#39;re like Poindexter and…” Eris searched briefly for the perfect reference, then landed on it: Pinky and the Brain, mutant lab mice from a 1990s cartoon who plot misguided schemes of world domination. “One is a genius, the other&#39;s insane,” she said, riffing on the theme tune. “But which one is which?”&lt;/p>;&lt;p data-caps=&quot;initial&quot;>;&lt;span data-caps=&quot;initial&quot;>;B&lt;/span>;ack at Eris&#39;s apartment, she slouched over a laptop as she scrolled through listings: “Massive cocaine and ketamine blowout sale”, read one. These, she said, were typical posts on the dark-web marketplace where &lt;small>;DULF&lt;/small>; buys its supply. Eris makes payments with cryptocurrency – their annual purchases are estimated to be in the hundreds of thousands of dollars – and picks up the packages at the post office. &lt;/p>;&lt;figure>;&lt;span itemscope=&quot;&quot; itemProp=&quot;image&quot; itemType=&quot;https://schema.org/ImageObject&quot;>;&lt;meta itemProp=&quot;url&quot; content=&quot;https://www.economist.com/img/b/1549/1032/90/media-assets/image/1843_20230908_1843_DRUGS_14.jpg&quot;/>;&lt;img loading=&quot;lazy&quot; width=&quot;1549&quot; height=&quot;1032&quot; src=&quot;https://www.economist.com/img/b/1549/1032/90/media-assets/image/1843_20230908_1843_DRUGS_14.jpg&quot; srcSet=&quot;https://www.economist.com/img/b/200/133/90/media-assets/image/1843_20230908_1843_DRUGS_14.jpg 200w,https://www.economist.com/img/b/300/200/90/media-assets/image/1843_20230908_1843_DRUGS_14.jpg 300w,https://www.economist.com/img/b/400/266/90/media-assets/image/1843_20230908_1843_DRUGS_14.jpg 400w,https://www.economist.com/img/b/600/400/90/media-assets/image/1843_20230908_1843_DRUGS_14.jpg 600w,https://www.economist.com/img/b/640/426/90/media-assets/image/1843_20230908_1843_DRUGS_14.jpg 640w,https://www.economist.com/img/b/800/533/90/media-assets/image/1843_20230908_1843_DRUGS_14.jpg 800w,https://www.economist.com/img/b/1000/666/90/media-assets/image/1843_20230908_1843_DRUGS_14.jpg 1000w,https://www.economist.com/img/b/1280/853/90/media-assets/image/1843_20230908_1843_DRUGS_14.jpg 1280w&quot; sizes=&quot;(min-width: 720px) 640px, 95vw&quot; alt=&quot;&quot;/>;&lt;/span>;&lt;/figure>;&lt;figure>;&lt;span itemscope=&quot;&quot; itemProp=&quot;image&quot; itemType=&quot;https://schema.org/ImageObject&quot;>;&lt;meta itemProp=&quot;url&quot; content=&quot;https://www.economist.com/img/b/1010/1386/90/media-assets/image/1843_20230908_1843_DRUGS_13.jpg&quot;/>;&lt;img loading=&quot;lazy&quot; width=&quot;1010&quot; height=&quot;1386&quot; src=&quot;https://www.economist.com/img/b/1010/1386/90/media-assets/image/1843_20230908_1843_DRUGS_13.jpg&quot; srcSet=&quot;https://www.economist.com/img/b/200/274/90/media-assets/image/1843_20230908_1843_DRUGS_13.jpg 200w,https://www.economist.com/img/b/300/412/90/media-assets/image/1843_20230908_1843_DRUGS_13.jpg 300w,https://www.economist.com/img/b/400/549/90/media-assets/image/1843_20230908_1843_DRUGS_13.jpg 400w,https://www.economist.com/img/b/600/823/90/media-assets/image/1843_20230908_1843_DRUGS_13.jpg 600w,https://www.economist.com/img/b/640/878/90/media-assets/image/1843_20230908_1843_DRUGS_13.jpg 640w,https://www.economist.com/img/b/800/1098/90/media-assets/image/1843_20230908_1843_DRUGS_13.jpg 800w,https://www.economist.com/img/b/1000/1372/90/media-assets/image/1843_20230908_1843_DRUGS_13.jpg 1000w,https://www.economist.com/img/b/1280/1757/90/media-assets/image/1843_20230908_1843_DRUGS_13.jpg 1280w&quot; sizes=&quot;(min-width: 720px) 640px, 95vw&quot; alt=&quot;&quot;/>;&lt;/span>;&lt;/figure>;&lt;figure>;&lt;span itemscope=&quot;&quot; itemProp=&quot;image&quot; itemType=&quot;https://schema.org/ImageObject&quot;>;&lt;meta itemProp=&quot;url&quot; content=&quot;https://www.economist.com/img/b/1792/1197/90/media-assets/image/1843_20230908_1843_DRUGS_15.jpg&quot;/>;&lt;img loading=&quot;lazy&quot; width=&quot;1792&quot; height=&quot;1197&quot; src=&quot;https://www.economist.com/img/b/1792/1197/90/media-assets/image/1843_20230908_1843_DRUGS_15.jpg&quot; srcSet=&quot;https://www.economist.com/img/b/200/134/90/media-assets/image/1843_20230908_1843_DRUGS_15.jpg 200w,https://www.economist.com/img/b/300/200/90/media-assets/image/1843_20230908_1843_DRUGS_15.jpg 300w,https://www.economist.com/img/b/400/267/90/media-assets/image/1843_20230908_1843_DRUGS_15.jpg 400w,https://www.economist.com/img/b/600/401/90/media-assets/image/1843_20230908_1843_DRUGS_15.jpg 600w,https://www.economist.com/img/b/640/428/90/media-assets/image/1843_20230908_1843_DRUGS_15.jpg 640w,https://www.economist.com/img/b/800/534/90/media-assets/image/1843_20230908_1843_DRUGS_15.jpg 800w,https://www.economist.com/img/b/1000/668/90/media-assets/image/1843_20230908_1843_DRUGS_15.jpg 1000w,https://www.economist.com/img/b/1280/855/90/media-assets/image/1843_20230908_1843_DRUGS_15.jpg 1280w&quot; sizes=&quot;(min-width: 720px) 640px, 95vw&quot; alt=&quot;&quot;/>;&lt;/span>;&lt;figcaption>;&lt;b>;Measure for measure &lt;/b>;The DULF has all its drugs tested (&lt;i>;top&lt;/i>;). Eris was working at a homeless shelter before founding the DULF (&lt;i>;middle&lt;/i>;). A price list for the shop (&lt;i>;bottom&lt;/i>;) &lt;/figcaption>;&lt;/figure>;&lt;p>;Finding a reliable vendor took time. &lt;small>;DULF&lt;/small>; needed large volumes at cheap prices; they had to be sourced from a seller in Canada, to avoid international drug-smuggling charges, and the drugs needed to be clean. It was a process of trial and error – buyers can seek refunds by opening a dispute on the site if they receive a tainted product – before they settled on a single vendor. “Whoever this person is obviously has an operation of some kind,” said Eris. One justification for the compassion club&#39;s model is that it would take money away from organised crime rings by selling medical-grade products from legitimate sources. Buying drugs on the dark web from an anonymous entity undermined that argument, as the health ministry noted in its letter rejecting the pair&#39;s shop. But lacking the necessary permits, &lt;small>;DULF&lt;/small>; would struggle to find a pharmaceutical alternative. “I don&#39;t know, and I don&#39;t want to know,” Eris said of their vendor&#39;s identity. &lt;/p>;&lt;p>;&lt;cite>;People continue to die: drug deaths in British Columbia&lt;!-- -->; are on pace for their highest year since the crisis was declared&lt;/cite>;&lt;/p>;&lt;p>;Drug trafficking is, of course, illegal in Canada. But laws have stretched to accommodate &lt;a href=&quot;https://www.economist.com/the-americas/2023/02/23/one-canadian-province-has-decriminalised-drugs&quot;>;harm reduction in British Columbia&lt;/a>;. The Canadian government decriminalised the possession of small amounts of hard drugs there in January, to encourage people to seek health care without fear of prosecution. Few now believe that decriminalisation has made much difference to the number of drug-related deaths; Vancouver police had all but abandoned arrests for simple possession anyway, and the street supply remained toxic. Fentanyl has largely displaced heroin, and drugs are increasingly &lt;a href=&quot;https://www.economist.com/united-states/2023/08/24/the-rise-of-tranq-dope-is-making-americas-opioid-crisis-worse&quot;>;tainted with benzodiazepines&lt;/a>;, a type of depressant that is resistant to the usual life-saving overdose medications. &lt;/p>;&lt;div>;&lt;div>;&lt;div id=&quot;econ-3&quot;>;&lt;/div>;&lt;/div>;&lt;/div>;&lt;p>;The window for widely implementing harm-reduction measures in Canada may be closing. The leader of the opposition Conservative Party, Pierre Poilievre, has come out against safe-supply programmes of any kind. His motion in the House of Commons to redirect funding towards addiction treatment failed in May. Recent polling has his party ahead of Justin Trudeau&#39;s Liberals. “Conservatives in this country are giving us some real old-school drug-war talking points,” said Mullins of &lt;small>;VANDU&lt;/small>;. But community organising has got harder as drugs have become more poisonous – benzodiazepines can cause memory problems, which makes for more confused, less productive general meetings. And people continue to die: drug deaths in British Columbia&lt;!-- -->; are on pace for their highest year since the crisis was declared. &lt;/p>;&lt;figure>;&lt;span itemscope=&quot;&quot; itemProp=&quot;image&quot; itemType=&quot;https://schema.org/ImageObject&quot;>;&lt;meta itemProp=&quot;url&quot; content=&quot;https://www.economist.com/img/b/1263/843/90/media-assets/image/1843_20230908_1843_DRUGS_16.jpg&quot;/>;&lt;img loading=&quot;lazy&quot; width=&quot;1263&quot; height=&quot;843&quot; src=&quot;https://www.economist.com/img/b/1263/843/90/media-assets/image/1843_20230908_1843_DRUGS_16.jpg&quot; srcSet=&quot;https://www.economist.com/img/b/200/133/90/media-assets/image/1843_20230908_1843_DRUGS_16.jpg 200w,https://www.economist.com/img/b/300/200/90/media-assets/image/1843_20230908_1843_DRUGS_16.jpg 300w,https://www.economist.com/img/b/400/267/90/media-assets/image/1843_20230908_1843_DRUGS_16.jpg 400w,https://www.economist.com/img/b/600/400/90/media-assets/image/1843_20230908_1843_DRUGS_16.jpg 600w,https://www.economist.com/img/b/640/427/90/media-assets/image/1843_20230908_1843_DRUGS_16.jpg 640w,https://www.economist.com/img/b/800/534/90/media-assets/image/1843_20230908_1843_DRUGS_16.jpg 800w,https://www.economist.com/img/b/1000/667/90/media-assets/image/1843_20230908_1843_DRUGS_16.jpg 1000w,https://www.economist.com/img/b/1280/854/90/media-assets/image/1843_20230908_1843_DRUGS_16.jpg 1280w&quot; sizes=&quot;(min-width: 720px) 640px, 95vw&quot; alt=&quot;&quot;/>;&lt;/span>;&lt;/figure>;&lt;figure>;&lt;span itemscope=&quot;&quot; itemProp=&quot;image&quot; itemType=&quot;https://schema.org/ImageObject&quot;>;&lt;meta itemProp=&quot;url&quot; content=&quot;https://www.economist.com/img/b/1263/843/90/media-assets/image/1843_20230908_1843_DRUGS_17.jpg&quot;/>;&lt;img loading=&quot;lazy&quot; width=&quot;1263&quot; height=&quot;843&quot; src=&quot;https://www.economist.com/img/b/1263/843/90/media-assets/image/1843_20230908_1843_DRUGS_17.jpg&quot; srcSet=&quot;https://www.economist.com/img/b/200/133/90/media-assets/image/1843_20230908_1843_DRUGS_17.jpg 200w,https://www.economist.com/img/b/300/200/90/media-assets/image/1843_20230908_1843_DRUGS_17.jpg 300w,https://www.economist.com/img/b/400/267/90/media-assets/image/1843_20230908_1843_DRUGS_17.jpg 400w,https://www.economist.com/img/b/600/400/90/media-assets/image/1843_20230908_1843_DRUGS_17.jpg 600w,https://www.economist.com/img/b/640/427/90/media-assets/image/1843_20230908_1843_DRUGS_17.jpg 640w,https://www.economist.com/img/b/800/534/90/media-assets/image/1843_20230908_1843_DRUGS_17.jpg 800w,https://www.economist.com/img/b/1000/667/90/media-assets/image/1843_20230908_1843_DRUGS_17.jpg 1000w,https://www.economist.com/img/b/1280/854/90/media-assets/image/1843_20230908_1843_DRUGS_17.jpg 1280w&quot; sizes=&quot;(min-width: 720px) 640px, 95vw&quot; alt=&quot;&quot;/>;&lt;/span>;&lt;/figure>;&lt;figure>;&lt;span itemscope=&quot;&quot; itemProp=&quot;image&quot; itemType=&quot;https://schema.org/ImageObject&quot;>;&lt;meta itemProp=&quot;url&quot; content=&quot;https://www.economist.com/img/b/1830/1220/90/media-assets/image/1843_20230908_1843_DRUGS_18.jpg&quot;/>;&lt;img loading=&quot;lazy&quot; width=&quot;1830&quot; height=&quot;1220&quot; src=&quot;https://www.economist.com/img/b/1830/1220/90/media-assets/image/1843_20230908_1843_DRUGS_18.jpg&quot; srcSet=&quot;https://www.economist.com/img/b/200/133/90/media-assets/image/1843_20230908_1843_DRUGS_18.jpg 200w,https://www.economist.com/img/b/300/200/90/media-assets/image/1843_20230908_1843_DRUGS_18.jpg 300w,https://www.economist.com/img/b/400/267/90/media-assets/image/1843_20230908_1843_DRUGS_18.jpg 400w,https://www.economist.com/img/b/600/400/90/media-assets/image/1843_20230908_1843_DRUGS_18.jpg 600w,https://www.economist.com/img/b/640/427/90/media-assets/image/1843_20230908_1843_DRUGS_18.jpg 640w,https://www.economist.com/img/b/800/533/90/media-assets/image/1843_20230908_1843_DRUGS_18.jpg 800w,https://www.economist.com/img/b/1000/667/90/media-assets/image/1843_20230908_1843_DRUGS_18.jpg 1000w,https://www.economist.com/img/b/1280/853/90/media-assets/image/1843_20230908_1843_DRUGS_18.jpg 1280w&quot; sizes=&quot;(min-width: 720px) 640px, 95vw&quot; alt=&quot;&quot;/>;&lt;/span>;&lt;/figure>;&lt;figure>;&lt;span itemscope=&quot;&quot; itemProp=&quot;image&quot; itemType=&quot;https://schema.org/ImageObject&quot;>;&lt;meta itemProp=&quot;url&quot; content=&quot;https://www.economist.com/img/b/1263/843/90/media-assets/image/1843_20230908_1843_DRUGS_20.jpg&quot;/>;&lt;img loading=&quot;lazy&quot; width=&quot;1263&quot; height=&quot;843&quot; src=&quot;https://www.economist.com/img/b/1263/843/90/media-assets/image/1843_20230908_1843_DRUGS_20.jpg&quot; srcSet=&quot;https://www.economist.com/img/b/200/133/90/media-assets/image/1843_20230908_1843_DRUGS_20.jpg 200w,https://www.economist.com/img/b/300/200/90/media-assets/image/1843_20230908_1843_DRUGS_20.jpg 300w,https://www.economist.com/img/b/400/267/90/media-assets/image/1843_20230908_1843_DRUGS_20.jpg 400w,https://www.economist.com/img/b/600/400/90/media-assets/image/1843_20230908_1843_DRUGS_20.jpg 600w,https://www.economist.com/img/b/640/427/90/media-assets/image/1843_20230908_1843_DRUGS_20.jpg 640w,https://www.economist.com/img/b/800/534/90/media-assets/image/1843_20230908_1843_DRUGS_20.jpg 800w,https://www.economist.com/img/b/1000/667/90/media-assets/image/1843_20230908_1843_DRUGS_20.jpg 1000w,https://www.economist.com/img/b/1280/854/90/media-assets/image/1843_20230908_1843_DRUGS_20.jpg 1280w&quot; sizes=&quot;(min-width: 720px) 640px, 95vw&quot; alt=&quot;&quot;/>;&lt;/span>;&lt;figcaption>;&lt;b>;Breaking good &lt;/b>;Jeremy estimates the shop&#39;s annual purchases are in the hundreds of thousands of dollars. Eris sells drugs to a DULF member (&lt;i>;second from top&lt;/i>;). She demonstrates how the drugs are packaged when they arrive from the dark web (&lt;i>;second from bottom&lt;/i>;). The pair started operating the DULF shop in the summer of 2022 (&lt;i>;bottom&lt;/i>;) &lt;/figcaption>;&lt;/figure>;&lt;p>;At &lt;small>;VANDU&lt;/small>;&#39;s community space, Mullins looked across a grey meeting room, where the board convenes. The group&#39;s mission statement – which pledges to ensure that “drug users have a real voice in their community” – is painted on the wall. Farther along are photos of dead leaders. “I never used to believe in ghosts,” Mullins said. “But I think I do now. I know so many people that have died. I sit in this room, and somebody says something, and I just know that my friend is going to have this little cliché line he always says. And I turn.” Mullins turned. “And he&#39;s been dead for six months. So the line doesn&#39;t get said. But I hear it. I can almost feel the guy there. So, I guess I feel haunted.”&lt;/p>;&lt;p data-caps=&quot;initial&quot;>;&lt;span data-caps=&quot;initial&quot;>;D&lt;/span>;ULF&#39;s shop was quiet, which was typical for a weekend. Then, shortly before closing, about a dozen members turned up. Monthly welfare cheques had gone out the previous week, and noisy customers had to queue for use of the three metal tables. The shop did over C$2,000 in sales that day. Like every day it had been open, no one overdosed in the space – and no one died.&lt;/p>;&lt;p>;&lt;cite>;“I never used to believe in ghosts. But I think I do now. I know so many people that have died”&lt;/cite>;&lt;/p>;&lt;p>;Media attention felt important to &lt;small>;DULF&lt;/small>; in the beginning, but it made their work harder. “People look up Drug User Liberation Front, and it&#39;s like, &#39;Look at this crazy transexual bitch handing out heroin to the homeless,&#39;” Eris said. The organisation also had trouble opening a bank account. Eris suspects her manner might put people off. “I have a folder in my email called &#39;death threats&#39;,” she confided. &lt;/p>;&lt;p>;&lt;small>;DULF&lt;/small>;&#39;s focus now is more narrow: prove the model works, and establish its legality in court. It has appealed the health ministry&#39;s rejection of its drug-law exemption request, and is preparing its case. Precedent may be in the group&#39;s favour. After North America&#39;s first supervised injection site, Insite, opened in Vancouver in 2003, it was challenged all the way to the Supreme Court, but survived. Insite, too, had been preceded by an illegal proof of concept. Eris and Jeremy hope that &lt;small>;DULF&lt;/small>; will emulate that path: a criminal enterprise one day, a public-health success the next. &lt;span data-ornament=&quot;ufinish&quot;>;■&lt;/span>;&lt;/p>;&lt;p>;&lt;b>;Sam Colbert&lt;/b>; produces podcast series for &lt;i>;The Economist&lt;/i>;&lt;/p>;&lt;p>;&lt;small>;PHOTOGRAPHS BY &lt;b>;Jackie Dives&lt;/b>;&lt;/small>;&lt;/p>;</description><pubDate> Tue, 12 Sep 2023 23:27:02 +0800</pubDate></item></channel></rss>